Prednisolone acetate 1% ophthalmic suspension — VA solicitation

Outcome

Submissions closed on 14 October 2026. No award has been published yet. Open tenders like this one are listed below.

SAM.gov’s current opportunity API reports the description as “N/A”; the official public attachment list provides the full SF-1449 solicitation as a DOCX. The original solicitation text is included from its invitation/schedule and Scope of Contract, all solicitation provisions E.1–E.10, and the payment/delivery portions of C.1 plus C.2–C.4. The standard non-payment C.1 clauses and separate Section D contract documents/exhibits are outside this notice transcription; see the private provenance record for exact boundaries. The attachment’s prices and award fields are blank.

Place
United States
Offer submission deadline
07:30 PM · UTC
Contract value
Not stated in the notice
Lots
3 lots
Classification
Pharmaceutical supplies
Published
September 30, 2026
SAM.gov

Overview

The VA’s public solicitation seeks offers for prednisolone acetate 1% ophthalmic suspension in 5 mL, 10 mL and 15 mL bottles. It lists estimated annual quantities of 392,107, 70,070 and 10,172 bottles, with a one-year base period and four one-year options. One aggregate firm-fixed-price requirements award was contemplated, subject to technical acceptability and lowest evaluated price. The deadline has passed. No prices, awardee or award are shown in the reviewed material.

Information based on the public notice

What the buyer needs

Supply solicitation for the three listed package sizes of prednisolone acetate 1% ophthalmic suspension through Government Pharmaceutical Prime Vendor programs.

  • Offers had to price all three items for the base year and all four option years.
  • The solicitation requires FDA-approved products, distinct 11-digit NDCs, and FDA cGMP-acceptable places of performance.

Lots

1 ·Prednisolone acetate 1% ophthalmic suspension, 5 mL bottles

2 ·Prednisolone acetate 1% ophthalmic suspension, 10 mL bottles

3 ·Prednisolone acetate 1% ophthalmic suspension, 15 mL bottles

Tender details

Buyer
U.S. Department of Veterans Affairs
Country
United States
Procedure
Solicitation
Classification
Pharmaceutical supplies · NAICS 325412 · PSC 6505
Notice reference
1d0a91a5d520424ab19ecfa35b34bd89 · 36E79726R0037
Solicitation number
36E79726R0037
Product
Prednisolone acetate 1% ophthalmic suspension
Packages and estimated annual quantity
5 mL: 392,107 bottles; 10 mL: 70,070; 15 mL: 10,172
Period
One-year base ordering period plus four one-year option periods
Offer deadline
14 October 2026, 14:30 America/Chicago (19:30 UTC)
Evaluation
Lowest price among technically acceptable offers; one aggregate award contemplated

What to check in the tender documents

  • The schedule’s unit-price and amount cells are blank; no total estimated contract value is stated.
  • No awardee, award date, or executed contract is identified in the reviewed official API or posted solicitation.
Get started with Ziva

Original notice

Read the original description

6505--Prednisolone 1% Ophthalmic Solution

Continuation of SF-1449, Block 3: The following information shall be entered by the Contracting Officer at the time of contract award according to the timeframes specified in this solicitation’s Section B, Scope of Contract, Section 1.4 Contract Effective Date, Implementation Period, and Ordering Period. Contract Award/Effective Date: ___________________ Implementation Period: __________________________ Ordering Period (Base Year): _____________________ Offerors shall not enter information into the above fields. Continuation of SF-1449, Blocks 19 through 24: Line items 1 - 3 To be considered for award, offerors must submit a price for line items 1, 2, and 3 for the base year and all four option years. One award will be made in the aggregate for line items 1, 2, and 3 for the base year and all four option years. Offered prices shall not exceed two decimal places. Note: NDC is defined as National Drug Code. ANDA is defined as Abbreviated New Drug Application. Line Item 1 Prednisolone Acetate 1% Ophthalmic Suspension 5ML NDC # __________________ ANDA#_________________ Schedule of Supplies | Quantity | Unit | Unit Price | Amount (Unit Price x Quantity) Base Year | 392,107 | Bottles | Option Year One | 392,107 | Bottles | Option Year Two | 392,107 | Bottles | Option Year Three | 392,107 | Bottles | Option Year Four | 392,107 | Bottles | Line Item 2 Prednisolone Acetate 1% Ophthalmic Suspension 10ML NDC # __________________ ANDA#_________________ Schedule of Supplies | Quantity | Unit | Unit Price | Amount (Unit Price x Quantity) Base Year | 70,070 | Bottles | Option Year One | 70,070 | Bottles | Option Year Two | 70,070 | Bottles | Option Year Three | 70,070 | Bottles | Option Year Four | 70,070 | Bottles | Line Item 3 Prednisolone Acetate 1% Ophthalmic Suspension 15ML NDC # __________________ ANDA#_________________ Schedule of Supplies | Quantity | Unit | Unit Price | Amount (Unit Price x Quantity) Base Year | 10,172 | Bottles | Option Year One | 10,172 | Bottles | Option Year Two | 10,172 | Bottles | Option Year Three | 10,172 | Bottles | Option Year Four | 10,172 | Bottles | SECTION B - CONTINUATION OF SF-1449 BLOCKS CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES Please be advised, the following paragraphs are also included elsewhere in the solicitation, but are included here for offeror reference. Proposals will be accepted in Microsoft Word or PDF format via e-mail at [direct contact value redacted] and [direct contact value redacted] with a scanned (pdf) copy of the signed SF-1449. Please note that faxed proposals are not acceptable and will be rejected. Please note, zip files and folders are rejected by the Department of Veterans Affairs (VA) Enterprise Procurement Office (EPO) servers, and emails with large attachments may not be received. VA suggests that offerors submit their proposals well before the deadline and confirm receipt of all attachments with the Contracting Officer listed on the SF-1449. If the offeror is not the manufacturer of the offered items, the offeror shall submit a Letter of Commitment from the manufacturer to the offeror which will assure the offeror of a source of supply sufficient to satisfy the Government's requirements for the contract period. For the purposes of the Letter of Commitment and current Good Manufacturing Practices (cGMP) acceptability verifications (refer to the solicitation’s Scope of Contract for cGMP details), “Manufacturer” is defined as the entity which is engaged in the production, preparation, propagation, compounding, conversion, or processing of active and inactive ingredients to form drug products, whether directly or indirectly by extraction from substances of natural origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis. This process includes the measuring, mixing, weighing, and compounding both the active and inactive ingredients. The product is then converted into various drug forms, suitable for administration through tablets, capsules, liquids (in the form of solutions, suspensions, emulsions, gels, or injectables), creams, ointments, or aerosols. An acceptable Letter of Commitment is required from all distributor-offerors to be eligible for award. The offeror must maintain the same manufacturer and New Drug Application (NDA)/Abbreviated New Drug Application (ANDA)/Biologics License Application (BLA) for the duration of the contract period, unless the Contracting Officer makes a determination that a change in the manufacturer is acceptable. This determination may take place before or after contract award. If the offeror is not a manufacturer, to be eligible for award, offerors must submit a Letter of Commitment that meets all requirements stated in the Addendum to FAR 52.212-1 Instructions to Offerors-Commercial Products and Commercial Services. One award will be made in the aggregate for all line items for the base year, including all four option years. To be considered for award, offerors must propose a price for line items 1, 2, and 3 for the base year and each option year. Proposals that fail to include a price for the base year and each of the four option years for line items 1, 2, and 3 may be rejected and receive no further consideration. (Refer to Schedule of Supplies for package size details and estimates) Offered prices shall include a 0.50% Cost Recovery Fee (See Scope of Contract, Section 12). The Government will evaluate offers in accordance with the policies and procedures of the FAR Part 12, Part 15, and Part 25. Acknowledgement of Amendments. The following amendments are acknowledged as part of this solicitation. (Please complete if applicable) Amendment Number | Date Acknowledged by Offeror The System for Award Management (SAM) is the Official U.S. Government system for registering to do business with the federal government, completing company representations and certifications, listing contract opportunities, and more. Contractors/Offerors should go to http://www.sam.gov to find their information. Training tools are available on the SAM website for familiarization with the SAM system. Prospective contractors shall maintain an uninterrupted, current, and accurate record in the SAM database at the time of proposal submission, during evaluation, and during contract performance. SAM updates are required as necessary, but at least annually. System updates may lag policy updates. The System for Award Management (SAM) may continue to require entities to complete representations based on provisions that are not included in this solicitation. Contracting officers will rely on representations from offers based on provisions in the solicitation. Entities are not required to, nor are they able to, update their entity registration to remove these representations in SAM. Subcontracting Plan Requirements: Pursuant to the requirements of 15 U.S.C. § 644, all other than small business concerns are required to have an approved subcontracting plan for contracts valued over $900,000 before the Government can award a contract (see FAR 52.219-9 and VAAR 852.219-70 for details). Offerors must submit a currently approved commercial plan or a new plan for review and approval. Attachment “D” includes all of the elements required to be addressed and is included to facilitate the submission of a subcontracting plan. As prescribed in FAR Subpart 42.11, the Department of Veterans Affairs (VA) evaluates contractor performance on all contracts that exceed the Simplified Acquisition Threshold and shares those evaluations with other federal government agencies. The FAR requires that the contractor be provided an opportunity to comment on past performance evaluations prior to each report closing. To fulfill this requirement, VA will be using an online database, the Contractor Performance Assessment Reporting System (CPARS). Annual reporting of past performance will be completed at http://www.cpars.gov. SCOPE OF CONTRACT 1. INTRODUCTION 1.1 Background. All Ordering Activities under the VA and all Ordering Activities under the Department of Defense (DoD) acquire their pharmaceutical requirements through their respective Pharmaceutical Prime Vendor (PPV) Programs, hereafter referred to as the VA PPV Program and DoD PPV Program or jointly as PPV Programs. The PPV Programs are separate contracts which establish the fees for the distribution of pharmaceutical products that are distributed through the PPV Programs on Federal Government (i.e., Federal Supply Schedules, National Standardization) contracts. A contract resulting from this solicitation establishes the VA National Contract prices for the products listed in the schedule of supplies that will be distributed through the PPV Programs. Section 2.1, “Government Participants” lists the PPV Program participants that will be authorized users of the contract resulting from this solicitation. 1.2 Purpose and Objectives. The purpose of this solicitation is to establish a supply source that will provide the drugs listed in the schedule for purchase through the PPV Programs. The total annual estimated usage for VA, Federal Health Care Center (FHCC), State Veterans Homes (SVH) - Option 2, DoD, Indian Health Service (IHS), and Bureau of Prisons (BOP) appears on the Schedule of Supplies section of this Solicitation. The objective of such a contract is to ensure availability and consistency of product for nationwide usage and to obtain volume-based, committed-use pricing. 1.3 Government Purchase Compliance. VA, FHCC, SVH (Option 2), DoD, IHS, and BOP will purchase their requirements for the strengths of the drugs listed in the schedule through the PPV Programs except when: (1) the contracted items are unavailable to meet the needs of the Government, or (2) an alternate is requested by the prescribing healthcare provider, or (3) additionally, IHS will not participate if the awardee does not have a Centers of Medicare or Medicaid (CMS) reimbursable product(s). In the event that exception 1, 2, or 3 applies, these instances will be considered exceptions to FAR 52.216-21, Requirements. VA’s PPV contract has ordering lock-out procedures in place to support VA contract compliance and to prevent purchases of non-contract products. Participants of the VA PPV Program include VA, FHCC, SVH (Option 2), IHS, and BOP. DoD manages compliance through individual facility tracking reports. Contract Effective Date, Implementation Period, and Ordering Period. (A) Contract Effective Date. The contract will be effective on the date the Contracting Officer signs the SF-1449 and notifies the offeror (contractor) of award. (B) Implementation Period. The timeframe beginning on the Contract Effective Date and ending at the start of the Ordering Period in which PPVs begin placing orders with the contractor for delivery to the multiple PPV distribution centers is the Implementation Period. Contractors will be allowed a maximum of a 60-day Implementation Period (but may be shorter than 60 calendar days if mutually agreed between the contractor and the Government), if the contract is awarded after February 28, 2027. If the contract is awarded prior to February 28, 2027, the Implementation Period will begin when the contract is awarded and end on April 30, 2027. There are approximately 31 VA PPV Distribution Centers and approximately 25 DoD PPV Distribution Centers located nationwide. The contractor shall ensure that sufficient inventory of contract items awarded under this solicitation is available, and that chargeback agreements with the PPVs have been executed with sufficient time to permit the PPVs to begin timely distribution of Government orders by the expiration of the contract Implementation Period. The current PPVs are listed as attachments “A” and “B” of this solicitation. The current PPVs may change and the contractor will be notified of any changes in PPV contractors during the term of the contract resulting from this solicitation. Payment terms, time and place of delivery to PPV distribution centers, and other business-to-business agreement terms shall be agreed upon between the PPV contractors and the contractor awarded a contract from this solicitation. While it is a requirement that the contractor establish a business-to-business agreement with the PPVs, the Government is not a party to this business-to-business agreement and does not negotiate for either the Contractor or PPVs. The Contracting Officer shall be notified by the contractor if any business-to-business-agreements cannot be reached with the PPVs by 15 calendar days before commencement of the Ordering Period. Failure or refusal to reach agreement with the PPVs and maintain an agreement with the PPVs throughout the entire contract period shall constitute sufficient cause for terminating the contract under FAR 52.212-4(m), Contract Terms and Conditions-Commercial Products and Commercial Services, Termination for Cause. (C) Ordering Period. The Ordering Period begins at the expiration of the Implementation Period. The base year Ordering Period will be in effect for the period of one (1) year. During this period, Government participants place orders with the PPVs, who ship product to the Government participants. The PPVs shall order product from the Contractor and the Contractor shall ship to the PPVs in accordance with the terms of the Contractor and PPV business-to-business agreements. Failure to provide awarded product meeting all solicitation/contract requirements by the ordering period start date may result in contract termination in accordance with FAR 52.212-4(m), Contract Terms and Conditions-Commercial Products and Commercial Services, Termination for Cause. (D) At the time of contract award, the Contracting Officer shall indicate the contract Effective Date, Implementation Period, and Ordering Period on Page 2 of the SF-1449, in accordance with the timeframes specified in this section. 1.5 Contract Duration. The contract resulting hereunder will be in effect for the duration of the Implementation Period described in Section 1.4 plus one (1) year Ordering Period with four (4) one (1) year pre-priced option (ordering) periods that may be exercised unilaterally by the Government in accordance with FAR 17.204-1 and FAR 52.217-9. 1.6 Special Contract Considerations. As discussed in Section 1.2, this solicitation establishes a supply source to provide the drugs listed in the schedule for purchase through the PPV programs. Additionally, as outlined in Section 1.4, the awarded offeror (contractor) under this solicitation must reach and maintain a business-to-business agreement with the respective PPV programs for the duration of the contract. Because the PPV programs distribute the supplies sourced from this solicitation, special contract considerations apply. Under this resulting contract, the contractor will be receiving payments from the PPV programs instead of directly from the Government. Due to this unique payment structure, contractors are not permitted to assign their rights to receive payment under this contract. Additionally, disputes arising between a contractor and any authorized Government Prime Vendor(s) do not give rise to a “claim” under the Disputes Clause. Finally, no invoices will be provided from the contractor to the Government ordering facilities. Instead, the contractor shall submit invoices in accordance with the business-to-business agreements reached with the PPV programs. 2. EXTENT OF OBLIGATION 2.1 Government Participants. The contractor shall provide the products specified in the schedule at the prices awarded herein for the facilities/agencies below: All Department of Veterans Affairs (VA) facilities All Ordering Activities under the Department of Defense (DoD) Pharmaceutical Prime Vendor Program All Indian Health Service (IHS) facilities All Bureau of Prisons (BOP) facilities Captain James A. Lovell Federal Health Care Center (FHCC) All Option 2 State Veteran Homes (See Section 2.2 State Veteran Homes) A database of all facilities authorized to use the VA PPV Program may be downloaded from the Enterprise Procurement Office’s web site at http://www.va.gov/oal/business/nc/ppv.asp. 2.2 State Veteran Homes (SVHs). There are numerous SVHs that have entered into sharing agreements with VA Medical Centers (VAMCs). The SVHs with sharing agreements that participate in the VA PPV Program are identified as being one of two types: Option 1 or Option 2. Option 1: The SVH orders pharmaceuticals directly from the VA PPV and pays the VA PPV for all items purchased. An Option 1 SVH is not eligible for national contract prices awarded under this solicitation unless it is specifically named in the scope of contract or added after award by mutual agreement between the contractor and the Government. Option 2: The VAMC authorizes the SVH’s order, and the VAMC makes payment to the VA PPV for all pharmaceuticals ordered by the SVH. An Option 2 SVH is eligible for the national contract prices awarded under this solicitation. 2.3 Consolidated Mail Outpatient Pharmacies (CMOPs) (VA ONLY) and Tricare Mail Order Pharmacies (TMOPs) (DoD ONLY). Many drugs are prescribed and mailed directly to patients’ homes in three-month or 90-day supply and VA CMOPs/DoD TMOPs may place an initial order with the VA PPV/DoD PPV contractor for up to 30% of the estimated VA/DoD annual contract quantities immediately upon the commencement of the ordering period. An initial order of up to 30% of the estimated VA/DoD annual contract quantities may be placed by the VA PPV/DoD PPV contractor with the contractor awarded a contract under this solicitation to fulfill the CMOP and/or TMOP 30% initial order requirements. 2.4 Estimated Quantities. The quantities in the schedule reflect the combined usage of all VA (inclusive of FHCC and Option 2 SVH), DoD, IHS, and BOP activities currently participating in the PPV Programs. These estimated annual requirements do not include those of any other Government agency, including those currently participating in the VA PPV Program (e.g. Immigration and Customs Enforcement, Option 1 State Veteran’s Homes). The estimated usage cited in the Schedule is the Government’s total estimated usage for the strengths listed. There is no expressed or implied guarantee that the estimated quantity will be purchased under this contract. Actual quantities purchased may exceed or be less than those represented. 3. PRODUCT REGISTRATION Product information pertaining to all items offered under this solicitation, including the offeror’s unique National Drug Code(s) (NDC), must be submitted for registration to the Food and Drug Administration (FDA), First Databank, Oracle Cerner/Multum (Multum), and Medispan no later than five calendar days after notification of contract award. The awarded contractor shall notify the Contracting Officer if there are any issues delaying registration. A New Product Submission Form can be obtained by contacting First Databank at [direct contact value redacted], extension 566, or information can be obtained at http://www.fdbhealth.com/solutions/manufacturer-relations/. Multum information can be obtained and submitted at [direct contact value redacted]. Further information on the Oracle/Multum database is available at https://www.nlm.nih.gov/research/umls/rxnorm/sourcereleasedocs/mmsl.html. Medispan information can be obtained at https://www.wolterskluwer.com/en/solutions/medi-span. 4. NATIONAL CONTRACT ITEM BACKORDERS A contract awarded under this solicitation will be the Government’s primary source of supply (See FAR 52.216-21 Requirements). The Government’s ability to provide quality healthcare to its patient population is severely impaired when a national contract product is not available due to backorders. The purpose of this paragraph is to provide guidance to the awarded offeror (contractor) regarding a temporary solution to national contract item backorders that may be implemented in lieu of the Government terminating the contract for cause. However, consideration of this paragraph shall not waive any of the Government’s rights to terminate the contract for cause in accordance with FAR 52.212-4(m) Termination for Cause. For purposes of this contract, a backorder occurs when the PPVs issue an order with the contractor, and the complete order quantity is not delivered to the PPVs within 15 calendar days after receipt of order. This includes initial CMOP orders. If a national contract item is backordered by the PPVs, the Contracting Officer will investigate the backorder to determine if the national contract contractor bears responsibility for the backorder. The awarded contractor shall inform the Contracting Officer within four calendar days after a backorder occurs. In addition to informing the Contracting Officer of the backorder, the contractor shall provide an estimated date when the backorder will be shipped, and may propose a solution to satisfy the Government’s needs for the contract items until the backorder is resolved. The Government reserves the right to accept or reject any possible solutions that the contractor may propose to alleviate a national contract backorder situation. If the contracting officer determines that the contractor bears responsibility for the backorder, and the contractor is not able to provide a solution that is acceptable to the Government, (i.e., acceptable solution to the backorder, in lieu of Termination for Cause), the parties agree that the Government may buy against the contractor by acquiring the same or similar items from another source and billing the contractor for any excess procurement costs. In other words, if the Government must purchase product from another vendor because of a national contract backorder, the contractor will issue credit or reimburse the Government for the difference between the purchase price and the contract price within 30 calendar days after receipt of notification. The contractor shall also provide written verification to the Contracting Officer when credits or reimbursement have been made within 30 calendar days from date of reimbursement. After a backorder incident occurs for which the contractor is responsible, the Government’s decision to enter into a buy-against agreement described above will not deprive the Government of its right under FAR 52.212-4(m) to terminate the contract for a breach of the buy-against agreement, for a subsequent contractor-caused backorder, or for any other sufficient cause. 5. PACKAGING REQUIREMENTS Offerors must state the exact name and strength of the drug being supplied as it will appear on the label. Offerors shall also provide a unique 11-digit NDC number for all items offered; the NDC number must be specific to the offering company and to the drug being supplied. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. VA labels must be able to securely adhere on top of the successful offeror/contractor’s label. Glass bottles are not acceptable. All bottles must be compatible with automated dispensing units (Baxter ATC Canisters, Optifill, etc.). Items are identified in the Schedule of Supplies and in Attachment C. By submitting an offer in response to this solicitation, the offeror certifies that all offered products have passed any required stability testing for all proposed package sizes. 6. BAR CODING All pharmaceutical products provided under this contract shall include bar code labeling at the unit-of-use package level. The bar code labeling must be in a linear format that conforms to all GS1-128 (formerly EAN.UCC) or Health Industry Business Communication Council (HIBCC) Health Industry Bar Code (HIBC) supplier labeling standards. The bar code symbology must comply with all GS1 or HIBCC HIBC parameters including, but not limited to: symbology type or encoded pattern, bar and space dimensions and tolerances, and allowable ratio of wide to narrow elements. The bar code may be any linear bar code symbology such as GS1-128 (formerly EAN.UCC), GS1 DataBar (formerly RSS), or Universal Product Code (UPC) (if the UPC contains the National Drug Code or NDC). The bar code must encode the NDC, either alone or within the GS1 data structure (Global Trade Item Number (GTIN). The bar code printing must be American National Standards Institute (ANSI)/International Organization for Standardization (ISO)/IEC Quality Grade C or better. Manufacturers and packagers must ensure that production runs include an initial verification check, as well as routine audits to ensure the bar code is printed clearly and consistently to meet the quality standard of Grade C or better. Contractors shall be responsible for ensuring that bar code labels meet the quality requirements specified in this section prior to shipping pharmaceutical products to any Government Prime Vendor under this contract. The bar code must be on the outside container or wrapper of the medication as well as on the immediate container, unless the bar code is readily visible and machine-readable through the outside container or wrapper. When the bar code is not easily machine-readable through the over wrap, the over wrap must contain the bar code. If applicable, the bar code must go on each cell of a blister pack. Furthermore, the bar code must remain intact under normal conditions of use; thus it should not be printed across the perforations of a blister pack. When applicable to the symbology used, bar codes shall be surrounded by sufficient quiet zone so that the bar code can be scanned correctly. Bar code placement shall minimize curvature of the bar code. For example, bar codes should be placed in “ladder orientation” on vials or bottles to minimize curvature of the bar code. Bar code labeling shall not be placed solely on outer packaging. The Drug Supply Chain Security Act (DSCSA) now requires a two-dimensional data matrix bar code (GS-1 data matrix bar code preferred) for each product down to the lowest saleable package size (see Section 7, below, for additional DSCSA requirements); however, the FDA bar code rule for linear bar codes still applies to all packaging as stated above. A human readable number must be placed adjacent (preferably below) the encoded bar code to ensure product is usable with VA Bar Code Medication Administration (BCMA) in the event the bar code is in some way damaged. It is recommended that bar code labeling also include the lot number and expiration date. If two separate distinctive bar codes are used, one for NDC and the other for lot number/expiration date; the lot number and expiration date bar code must not be in close proximity to the NDC barcode or in a format that may be confused with the NDC bar code. When applicable, all Healthcare Distribution Alliance (HDA) guidelines (formerly HDMA) shall be followed. 7. DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) REQUIREMENTS Title II of the Drug Quality and Security Act (DQSA), known as the DSCSA, applies to all drug products, with the exception of those listed on the DSCSA exemption list: Title II of the Drug Quality and Security Act | FDA. As part of the requirement of the DSCSA, drug products are required to provide serialized DSCSA Transaction Information and Transaction Statements using GS1 industry standard Electronic Product Code Information Services (EPCIS) files following the GS1 US Implementation Guideline: The GS1 US DSCSA Implementation Suite (gatewaychecker.com) in order to transmit the files needed for tracking. DSCSA also requires that all trading partners of manufacturers, wholesale distributors, dispensers, and repackagers meet applicable requirements for being authorized trading partners. The National Association of Boards of Pharmacy (NABP) has established a trading partner directory, which is a repository of authorized trading partners that can be accessed to authenticate authorized trading partners in real time. All VA and other participating agency pharmacies will be entered in this directory as authorized trading partners using unique identifiers. Current and prospective trading partners of the VA other participating agencies are required to complete a registration prior to selling pharmaceuticals to these agencies. Neither the Government, nor the vendors will be charged a fee to participate in the directory. DSCSA drug products are required to provide the serialized DSCSA Transaction Information and Transaction Statement required for the interoperable electronic DSCSA system using GS1 industry standard EPCIS files following the GS1 US Implementation Guideline. Suppliers establishing an EPCIS connection for DSCSA will need to inform their trading partners of the master data for the Global Trade Item Number (GTIN) and Global Location Numbers (GLNs) that they utilize. These are necessary to establish the EPCIS connection in addition to being able to transmit the file using AS2 or another method. This onboarding must be complete as product may not be purchased or sold without the serial DSCSA Transaction Information. Registration and valid status in the National Association of Boards of Pharmacy (NABP) Trading Partner Directory is required also for all VA contract holders pursuant to DSCSA. 8. NATIONAL DRUG CODES Offerors shall provide a separate and distinct 11-digit NDC Number unique to the offeror (e.g., 00012-3456-78) for each product proposed, in the space provided following each item in block 20 of the SF-1449, “Schedule of Supplies and Prices” of the solicitation. The first five numbers of the 11-digit NDC number for each product proposed shall identify the offeror. Offerors must provide their own labeler code, to be used in the NDC number for the offered items. If an offeror is a dealer/distributor and does not have a labeler code, it must apply and be approved with the FDA for its own labeler code prior to making an offer under this solicitation. Offers that fail to provide the information required by this paragraph by the solicitation’s due date and time for receipt of offers may be rejected and receive no further consideration. 9. DRUG APPLICATION By signing this solicitation, the offeror certifies that it has on file (if any of the following are required by the FDA for the offered drugs): an FDA approved New Drug Application (NDA), an approved abbreviated NDA (ANDA), or an approved Biologics License Application (BLA), as appropriate for the items offered in response to the solicitation. 10. RECALLS If a drug recall is initiated for any drug provided under this contract, regardless of whether it is a voluntary recall by the manufacturer or a recall required by the FDA; or, if FDA withdraws its approval to manufacture any drug that is included on this contract, the contractor shall immediately forward the recall notification, along with any pertinent information via email to the assigned Contracting Officer and to the following: [direct contact value redacted] Chief, Pharmaceutical Division, Acquisition Service 7 VA Enterprise Procurement Office 1st Ave., 1 Block North of Cermak Rd., Bldg. 37 P.O. Box 76, Hines, IL 60141 [direct contact value redacted] Deputy Chief Consultant (M/S119D) VHA Pharmacy Benefits Management Services 1st Ave., 1 Block North of Cermak Rd., Bldg. 37, Rm 139 Hines, IL 60141 [direct contact value redacted] Manager, Product Recall Office National Center for Patient Safety Veterans Health Administration 24 Frank Lloyd Wright Drive, Lobby M Ann Arbor, MI 48106 [direct contact value redacted] Phone Number: [direct contact value redacted] All Government Prime Vendors that were sent shipments of the affected product(s) shall also be provided a copy of the recall notification along with any pertinent information. 11. COVERED DRUGS Should a covered drug (as defined in 38 U.S.C. § 8126(h)(2)) be proposed and awarded as a result of this solicitation, the awarded prices shall meet the requirements of 38 U.S.C. § 8126 and shall apply to all Government participants listed in Section 2.1 of the Scope of Contract, regardless of whether the participant is covered under the law. Therefore, prices for the base year and all option years shall not exceed the annually established Federal Ceiling Price (FCP), plus the 0.5% Cost Recovery Fee (CRF). Attention is directed to the fact that although 38 U.S.C. § 8126 applies to all covered drugs, competitively negotiated and awarded prices for the base year and any option years exercised by the Government will govern unless the annually established FCP results in a price lower than competitively awarded contract prices. In this instance, the contract shall be modified to reflect the lower annually established FCP, plus the 0.5% CRF. Both parties (Offeror and VA) understand the VA National Contract Service will obtain FCPs from VA’s Pharmacy Benefits Management (PBM). The parties agree the FCP will be calculated pursuant to the requirements of 38 U.S.C. § 8126 and any related requirements contained in the contractor’s Master Agreement, Pharmaceutical Pricing Agreement, and relevant VA Dear Manufacturer Letters. Refer to the VA Federal Supply Schedule (FSS) website at https://www.fss.va.gov/ and Public Law 102-585 (Veterans Health Care Act of 1992) page on the VA FSS website at https://www.va.gov/opal/nac/fss/publicLaw.asp for further information and a list of published Dear Manufacturer Letters. Contractors submitting a proposal for a covered drug are required to complete the following paragraph: MASTER AGREEMENTS AND PHARMACEUTICAL PRICING AGREEMENTS In compliance with 38 U.S.C. § 8126, Offerors of covered drug products (including biologics) must state below whether they currently have a Master Agreement (MA) and a Pharmaceutical Pricing Agreement (PPA), that includes the offered drug products/NDCs, in place with the Department of Veterans Affairs (VA) and confirm that the proposed covered drug products are present on the Offeror’s FSS contract or interim agreement. _____ YES, Offeror has an MA and PPA (inclusive of the proposed drug products/NDCs) in place with VA FSS and proposed drugs are present on Offeror’s FSS contract/interim agreement. _____ NO, Offeror does not have an MA and PPA (inclusive of the proposed drug products/NDCs) in place with VA FSS and/or products are not present on Offeror’s FSS contract/interim agreement. Offers of covered drugs (including biologics that fall within 21 CFR § 600.3) will only be considered for award if the Offeror has an executed MA and PPA (which includes the proposed drug products/NDCs) on file with the VA Enterprise Procurement Office, FSS (in accordance with 38 U.S.C. § 8126(h)(4)(B)). Furthermore, in order to be considered for award under this solicitation, all proposed covered drug products/NDCs must be present on the offeror’s FSS contract or interim agreement with an established Permanent FCP associated with the offeror’s FSS contract or interim agreement by this solicitation’s due date and time for receipt of offers. Offers failing to meet these criteria will be rejected and receive no further consideration. 12. COST RECOVERY FEE AND SUBMISSION OF QUARTERLY SALES REPORTS 12.1 Quarterly Sales Reports. The Contractor shall report all contract sales under this contract and submit collected Cost Recovery Fees as follows: (A) The Contractor shall accurately report the dollar value, in U.S. dollars and rounded to the nearest whole dollar, of all sales made under this contract by calendar quarter (January 1–March 31, April 1–June 30, July 1–September 30, and October 1–December 31). Reported sales must include all sales made to all authorized contract users, whether shipped directly to the users or through Prime Vendor contractors. The report shall reflect sales by contract line item and shall segment sales by the Department of Veterans Affairs (VA) and Other Government Agencies (OGA). A Cost Recovery Fee equivalent to 0.5 % of the current contract price shall be collected from all contract users. The 0.5 % Cost Recovery Fee shall be imbedded in the awarded contract prices, and offers submitted in response to this solicitation shall include the Cost Recovery Fee in every line item price offered. The reported contract sales shall include the Cost Recovery Fee and each quarterly report shall show the total Cost Recovery Fee amount collected on the reported sales. The Contractor shall maintain a consistent accounting method of sales reporting, based on the Contractor’s established commercial accounting practice. (B) Contract sales reports are due to the Contracting Officer within 30 calendar days following the completion of each reporting quarter or completion of the contract, whichever occurs first. A report is required even when no billings or invoices are issued or no orders are received during the contract period. (C) The sales report signed by an authorized representative of the contractor shall be emailed to the Contracting Officer. (D) In addition to the submission of quarterly sales reports due to the Contracting Officer within 30 calendar days after the end of each reporting quarter, contractors shall provide copies of sales reports simultaneously with contractor’s Cost Recovery Fee payment submissions via email to: [direct contact value redacted]. 12.2 The 0.5% Cost Recovery Fee amount shall be paid electronically via Collections Information Repository (CIR)/Automated Clearing House (ACH). CIR/ACH credit instructions will be provided to the contractor upon contract award. When the contractor has multiple national contracts, the fee may be consolidated into one electronic payment. When the electronic payment is made, the contractor shall submit an email to [direct contact value redacted] to identify the contract number (or numbers, if the payment covered multiple contracts) included, dollar amount remitted for each contract number, and reporting quarter. The Cost Recovery Fee payment is due to the VA Fiscal Division at the same time the sales report is due to the Contracting Officer (i.e., within 30 calendar days following the completion of each reporting quarter or completion of the contract). Cost Recovery Fee payments shall not be combined with any Industrial Fund Fee payments. Contractors shall remit separately any Industrial Fund Fee payments in support of any of the Contractor’s Federal Supply Schedule contracts. 12.3 The Government reserves the right to inspect without further notice, such records of the Contractor as pertain to sales under any contract resulting from this solicitation. Willful failure or refusal to furnish the required reports, or falsification thereof, shall constitute sufficient cause for terminating the contract under FAR 52.212-4(m), Contract Terms and Conditions - Commercial Products and Commercial Services, Termination for Cause. 12.4 Failure to remit the full amount of the Cost Recovery Fee within 30 calendar days after the end of the applicable reporting period constitutes a contract debt to the United States Government under the terms of FAR Subpart 32.6. The Government may exercise all rights under the Debt Collection Improvement Act of 1996, including withholding or setting off payments and interest on the debt (see FAR 52.212-4(i)(5)). Should the Contractor fail to submit the required sales reports, falsify them, or fail to timely pay the Cost Recovery Fee, the Government shall have, in addition to the rights and remedies described in this section, all other rights and remedies permitted by Federal law and statutes. 13. MANUFACTURING FACILITIES/PLACE OF PERFORMANCE 13.1 The FDA is the Government agency responsible for providing and enforcing pharmaceutical cGMP standards for human drugs, pharmaceutical products, biologics, medical devices, chemical products, medical cylinder oxygen, reagents, diagnostics, test kits and sets included in this solicitation. Only offers from companies that have an acceptable cGMP status on record with the FDA for the facilities identified by the offeror in Section 13.7 below will be considered for award. Before a contract can be awarded, any successful offeror’s manufacturing, packaging, and any other applicable facilities shall have a current acceptable cGMP status with the FDA, or shall have had an acceptable report from the last FDA facility inspection on record for the product type offered. In the absence of a current cGMP evaluation for any of the identified facilities, an offeror is required to include with its proposal documentation on the acceptable outcome of an FDA facility inspection that occurred within two years prior to submission of the offer. 13.2 If at any time during the life of the contract, the contractor’s facility (or the source from which the contractor obtains any of the products offered on this contract), or the facility that packages the product offered in this contract is notified of violations or potential violations by the FDA, is issued a Form FDA 483, or is issued an FDA Warning Letter highlighting a failure to meet FDA cGMPs (21 CFR Part 210 and 211), the awarded contractor shall inform the Contracting Officer within 15 calendar days of the notice. At which time, the Contracting Officer will apply the procedures outlined in Section 13.3 below. Non-timely notification may result in a negative past performance rating and/or be grounds for contract termination in accordance with FAR 52.212-4(m), Contract Terms and Conditions-Commercial Products and Commercial Services, Termination for Cause. 13.3 The Contracting Officer will review the contractor’s (or its source’s) unacceptable cGMP status with appropriate VHA clinical staff and will either: 1) instruct the contractor to stop the shipment of products listed on this contract that were manufactured and/or packaged in a facility with unacceptable cGMP status, or 2) authorize the contractor to continue to supply such contract products for 90 calendar days from the date when unacceptable cGMP status was communicated to VA EPO, provided that the products have not been subjected to a consumer-level recall. An additional 90 calendar day extension may be authorized at the discretion of the Contracting Officer. Contractors are cautioned that products that were manufactured and /or packaged in a facility with unacceptable cGMP status and then shipped without written authorization from the Contracting Officer shall be returned to the contractor at the contractor’s risk and expense. The contractor shall have corrected all significant cGMP deficiencies or have an acceptable plan with the FDA for the correction of such deficiencies which led to unacceptable status by the end of the 90-calendar day authorization period and any extensions of such period granted by the Contracting Officer. Additionally, the contractor is responsible for keeping the Contracting Officer informed of all corrections made and shall provide the Contracting Officer with: 1) written documentation of the correction plan, 2) Notification from FDA of acceptance of plan, and 3) a copy of any reinspection requests and subsequent reinspection reports, upon availability. If FDA’s evaluation of contractor’s (or its source’s) compliance efforts and/or re-inspection of the non-compliant facility does not result in an acceptable rating by the FDA within 90 calendar days from the date when unacceptable cGMP status was communicated to VA EPO, or by the end of a Contracting Officer’s authorization period (whichever is the greater period of time), the contract may be terminated for cause in accordance with FAR 52.212-4(m). The contractor’s (or its source’s) failure to correct the cGMP deficiencies in a timely manner shall not constitute or give rise to any “excusable delays” pursuant to FAR 52.212-4(f). (Nothing in this section shall be read as limiting the recognized grounds upon which a Contracting Officer may terminate this contract or delete products pursuant to the applicable sections contained in the contract.) 13.4 The contractor shall use only the FDA-inspected manufacturing facilities provided in Section 13.7, below, for the duration of the contract, unless substitution of manufacturing facilities is approved by the Contracting Officer. In case of any manufacturing facility relocation or substitution of manufacturing facilities, the contractor shall immediately notify the Contracting Officer of the pending change, and the contractor shall request approval from the Contracting Officer to supply the contracted products from the new location. If the change is approved by the Contracting Officer, after an inquiry to the FDA for cGMP status of the new location, approval will be provided by means of a formal contract modification. 13.5 If the products are to be manufactured at more than one location, each manufacturing facility and each facility address shall be listed along with the products manufactured at the facility. Subcontractors (i.e., packagers, labelers, etc.) that participate in the production of the products offered on this solicitation shall also be listed along with their addresses. All facilities described in this section and listed below shall be substantially in compliance with applicable FDA cGMP standards prior to contract award. 13.6 Offeror shall identify below or by attachment (if additional space is needed), the products offered on this solicitation (products shall be identified by product name and by solicitation item number); whether the offeror manufactures the products; and/or whether the offeror is a distributor of the products offered. Refer to the solicitation’s Continuation of Standard Form 1499: Schedule of Supplies/Services for the definition of “Manufacturer” for purposes of the Letter of Commitment and current Good Manufacturing Practices (cGMP) acceptability verifications. 13.7 The offeror is required to indicate below the complete name and address(es) of the manufacturer. The offeror is also required to check the box below that is applicable to its offer. Please note that the information required below must be the name and address of the manufacturing facility, rather than the address of the foreign headquarters, distributor or agent. ( ) OFFEROR IS THE MANUFACTURER (AT THE FOLLOWING LOCATIONS) OF THE PRODUCTS OFFERED ON THIS SOLICITATION. ( ) OFFEROR IS A DISTRIBUTOR OF THE PRODUCTS OFFERED ON THIS SOLICITATION. The offeror must maintain the same manufacturer (NDA/ANDA/BLA) for the duration of the contract period, unless the Contracting Officer makes a determination that a change in the manufacturer is acceptable. This determination may take place before or after contract award. THE PRODUCTS WILL BE MANUFACTURED BY THE FOLLOWING COMPANY AT THE FOLLOWING LOCATIONS: (Name of Manufacturing Company) (Street Address) (Post Office Address Not Acceptable) (U.S.A. Point of Contact, e-Mail Address and U.S.A Telephone Number) (FDA Establishment Identification [FEI] number of Manufacturing Company) PHARMACEUTICALS – PARENTERALS Solicitation Item # and Product Name | Location and owner of facility where ingredients are manufactured per definition in Scope of Contract, Section 13.6 (Facility Owner Name, Address, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number PHARMACEUTICALS – PARENTERALS, STERILIZATION Solicitation Item # and Product Name | Sterilization and owner location (Facility Owner Name, Address, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number ACTIVE PHARMACEUTICAL INGREDIENT (Also known as drug substance or bulk substance) Solicitation Item # and Product Name | Location and owner where active pharmaceutical ingredient is created (Facility Owner Name, Address, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number TABLETS, CAPSULES, AND PILLS Solicitation Item # and Product Name | Location and owner of facility where ingredients are manufactured per definition in Scope of Contract, Section 13.6 (Facility Owner Name, Address, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number OTHER PHARMACEUTICAL PRODUCTS (Solutions, syrups, mixtures, powders, ointments, pastes, creams, etc.) Solicitation Item # and Product Name | Location and owner of facility where ingredients are manufactured per definition in Scope of Contract, Section 13.6 (Facility Owner Name, Address, City, County, State and Zip Code | Point of Contact, Including Phone # | FEI Number PACKAGING (If product is repackaged, include both packaging and repackaging locations) Solicitation Item # and Product Name | Location of facilities where Intermediate containers will be filled and labeled (Facility Name, Location, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number PACKING Solicitation Item # and Product Name | Location of facilities where products will be packed and prepared for shipment (Facility Name, Location, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number 14. INCORPORATION OF DOCUMENTS The following documents are hereby incorporated by reference and made a part of this solicitation. The United States Pharmacopeia-National Formulary (USP-NF) designation "USP" and "NF" shall be considered interchangeable when monographs for ingredients or preparations are transferred from one official compendium to the other. For ingredients or preparations which no longer appear in the latest revision of the USP or NF, the previous volume shall apply. Ingredients or preparations for which monographs appear for the first time in the Official Compendia shall comply with the applicable monographs unless the word "modified" appears as part of the item name. The requirements that an item or ingredient comply with test standards and requirements of the USP or the NF does not delete any other applicable portions of the compendia, such as, but not limited to, General Notices. Thus, for USP-NF items, alternative test methods are permitted. AMERICAN CHEMICAL SOCIETY (ACS), Reagent Chemicals, American Chemical Society Specifications. Information about ACS Reagent Chemicals can be found at https://pubs.acs.org/. U. S. DEPARTMENT OF HEALTH, EDUCATION AND WELFARE, FOOD AND DRUG ADMINISTRATION (FDA). Federal Food, Drug, and Cosmetic Act and Regulations promulgated thereunder. FDA Rules and Regulations can be found at https://www.fda.gov/regulatory-information/fda-rules-and-regulations and can be found under Title 21 of the Code of Federal Regulation at https://www.ecfr.gov/. U. S. PHARMACOPEIAL CONVENTION, INC. (USP-NF). Pharmacopoeia of the United States. Information about USP/NF can be found at https://www.uspnf.com/. (g) Invoice. The Government will handle invoices according to the Prompt Payment Act (31 U.S.C. 3903) and 5 CFR part 1315. The Contractor shall submit invoices to the address designated in the contract to receive invoices. An invoice must include the information required by 5 CFR part 1315.9(b). (h) Patent indemnity. The Contractor shall indemnify the Government and its officers, employees, and agents against liability, including costs, for actual or alleged direct or contributory infringement of, or inducement to infringe, any United States or foreign patent, trademark, or copyright, arising out of the performance of this contract, provided the Contractor is reasonably notified of such claims and proceedings. (i) Payment— (1) Items accepted. Payment shall be made for items accepted by the Government that have been delivered to the delivery destinations set forth in this contract. (2) Prompt payment. The Government will make payment in accordance with the Prompt Payment Act ( 31 U.S.C. 3903) and prompt payment regulations at 5 CFR part 1315. (3) Discount. In connection with any discount offered for early payment, time shall be computed from the date of the invoice. For the purpose of computing the discount earned, payment shall be considered to have been made on the date that appears on the payment check or the specified payment date if an electronic funds transfer payment is made. (4) Overpayments. If the Contractor becomes aware of a duplicate contract financing or invoice payment or that the Government has otherwise overpaid on a contract financing or invoice payment, the Contractor shall— (i) Remit the overpayment amount to the payment office cited in the contract along with a description of the overpayment including the— (A) Circumstances of the overpayment (e.g., duplicate payment, erroneous payment, liquidation errors, date(s) of overpayment); (B) Affected contract number and delivery order number, if applicable; (C) Affected line item or subline item, if applicable; (D) Contractor point of contact; and (ii) Provide a copy of the remittance and supporting documentation to the Contracting Officer. (5) Interest.(i) All amounts that become payable by the Contractor to the Government under this contract shall bear simple interest from the date due until paid unless paid within 30 days of becoming due. The interest rate shall be the interest rate established by the Secretary of the Treasury as provided in 41 U.S.C. 7109, which is applicable to the period in which the amount becomes due, as provided in (i)(6)(v) of this clause, and then at the rate applicable for each six-month period as fixed by the Secretary until the amount is paid. (ii) The Government may issue a demand for payment to the Contractor upon finding a debt is due under the contract. (iii) Final decisions. The Contracting Officer will issue a final decision as required by FAR part 33 if– (A) The Contracting Officer and the Contractor are unable to reach agreement on the existence or amount of a debt within 30 days; (B) The Contractor fails to liquidate a debt previously demanded by the Contracting Officer within the timeline specified in the demand for payment unless the amounts were not repaid because the Contractor has requested an installment payment agreement; or (C) The Contractor requests a deferment of collection on a debt previously demanded by the Contracting Officer (see FAR part 32). (iv) If a demand for payment was previously issued for the debt, the demand for payment included in the final decision shall identify the same due date as the original demand for payment. (v) Amounts shall be due at the earliest of the following dates: (A) The date fixed under this contract. (B) The date of the first written demand for payment, including any demand for payment resulting from a termination for cause. (vi) The interest charge shall be computed for the actual number of calendar days involved beginning on the due date and ending on- (A) The date on which the designated office receives payment from the Contractor; (B) The date of issuance of a Government check to the Contractor from which an amount otherwise payable has been withheld as a credit against the contract debt; or (C) The date on which an amount withheld and applied to the contract debt would otherwise have become payable to the Contractor. (vii) The interest charge made under this clause may be reduced under the procedures for interest credits prescribed in FAR part 32 in effect on the date of this contract. (j) Risk of loss. Unless the contract specifically provides otherwise, risk of loss or damage to the supplies provided under this contract shall remain with the Contractor until, and shall pass to the Government upon— (1) Delivery of the supplies to a carrier, if transportation is f.o.b. origin; or (2) Delivery of the supplies to the Government at the destination specified in the contract, if transportation is f.o.b. destination. C.2 ADDENDUM to FAR 52.212-4 CONTRACT TERMS AND CONDITIONS--COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES 1. Ordering. This solicitation provides for the award of a contract in support of VA’s standardization program. Products awarded on the resultant contract will be distributed through Government Prime Vendor contract(s). Order placement for supplies awarded will be made by Government Prime Vendor contractor(s) to the awarded contractor and, any supplies to be furnished under this contract shall be ordered by issuance of delivery orders by the individuals or facilities directly to Prime Vendor contractor(s). Government Prime Vendor contractor(s) will accept orders and payment for the contracted item(s) on behalf of the Contractor. Such orders may be issued from the first day of the ordering period of the contract through the expiration date of the final option period exercised. All delivery orders are subject to the terms and conditions of this contract. In the event of conflict between a delivery order and this contract, the contract shall control. 2. Delivery. Delivery order requirements such as product quantities, time and place of delivery, and method of delivery for product(s) awarded on resultant contract will be determined between the awarded Contractor and Government Prime Vendor contractors. 3. Assignment. Application of 52.212-4(c) Assignment is dependent upon the details of the business-to-business agreement between the contractor and Pharmaceutical Prime Vendor. 4. Chargeback Arrangements. Chargeback arrangements/agreements shall be coordinated between the Government Prime Vendor contractors and the successful Contractor. The Government will not become involved in this area nor will the Government assume any responsibility for any monies involved with such arrangements. 5. Inspection/Acceptance. Products will be ordered by the Government through Government Prime Vendor contracts. The Government’s inspection rights become effective upon receipt at the Government ordering facility. 6. Risk of Loss. Unless the contract specifically provides otherwise, risk of loss or damage to the supplies provided under this contract shall remain with the Contractor, and shall pass to the Government upon delivery by the Contractor to any Government-contracted Prime Vendor contractor. C.3 52.216-21 REQUIREMENTS (VA DEVIATION NOV 2025) (a) This is a requirements contract for the supplies or services specified, and effective for the period stated, in the Schedule. The quantities of supplies or services specified in the Schedule are estimates only and are not purchased by this contract. Except as this contract may otherwise provide, if the Government's requirements do not result in orders in the quantities described as "estimated" or "maximum" in the Schedule, that fact shall not constitute the basis for an equitable price adjustment. (b) Delivery or performance shall be made only as authorized by orders issued in accordance with the Ordering clause. Subject to any limitations in the Order Limitations clause or elsewhere in this contract, the Contractor shall furnish to the Government all supplies or services specified in the Schedule and called for by orders issued in accordance with the Ordering clause. The Government may issue orders requiring delivery to multiple destinations or performance at multiple locations. (c) Except as this contract otherwise provides, the Government shall order from the Contractor all the supplies or services specified in the Schedule that are required to be purchased by the Government activity or activities specified in the Schedule. (d) The Government is not required to purchase from the Contractor requirements in excess of any limit on total orders under this contract. (e) If the Government urgently requires delivery of any quantity of an item before the earliest date that delivery may be specified under this contract, and if the Contractor will not accept an order providing for the accelerated delivery, the Government may acquire the urgently required goods or services from another source. (f) Any order issued during the effective period of this contract and not completed within that period shall be completed by the Contractor within the time specified in the order. The contract shall govern the Contractor's and Government's rights and obligations with respect to that order to the same extent as if the order were completed during the contract's effective period; provided, that the Contractor shall not be required to make any deliveries under this contract after 15 calendar days from the expiration date of the contract. C.4 ADDENDUM to FAR 52.216-21 REQUIREMENTS As detailed in the Addendum to FAR 52.212-4, products awarded on the resulting contract from this solicitation will be distributed through Government Prime Vendor contract(s). As such, details specific to contract(s) resulting from this solicitation regarding 52.216-21, Requirements, have been specified below. 1. Delivery or performance shall be made only as authorized by orders issued through Prime Vendor contract(s). Subject to any limitations specified in this contract, the Contractor shall deliver to the Prime Vendor contractor(s) the supplies specified in the Schedule and called for by orders issued by the Prime Vendor(s). Prime Vendor contractor(s) may issue orders requiring delivery to multiple Prime Vendor contractor distribution centers. 2. The Government shall order from the Contractor through the Prime Vendor contractor(s) all the supplies specified in the Schedule that are required to be purchased by the Department of Veterans Affairs and other Government agencies as specified in the Schedule. 3. If the Government urgently requires delivery of any quantity of an item that the Prime Vendor contractors(s) do not have available for delivery as required by the Prime Vendor contract terms, the Government may acquire the urgently required item(s) from any other available source. 4. Any order(s) issued by the Prime Vendor contractor(s) during the ordering period of this contract and not completed within the ordering period shall be completed by the Contractor within the time specified in the Prime Vendor contractor issued order. This contract shall govern the rights and obligations between the Contractor(s) of this contract, the Prime Vendor contractor(s) and the Government with respect to the order(s) to the same extent as if the order(s) were completed during the contract period, provided that, the Contractor shall not be required to make any deliveries under this contract after 15 calendar days from the expiration date of the contract. SECTION E - SOLICITATION PROVISIONS E.1 52.212-1 INSTRUCTIONS TO OFFERORS--COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES (VA DEVIATION 2025) (a) Submission of offers. Submit signed and dated offers to the office specified in this solicitation at or before the exact time specified in this solicitation. As a minimum, offers shall include— (1) The solicitation number; (2) The name, address, telephone number of the Offeror; (3) The Offeror’s Unique Entity Identifier (UEI) and, if applicable, Electronic Funds Transfer (EFT) indicator; (4) Information necessary to evaluate the factors contained in the provision at 52.212-2 or as described in the solicitation; (5) Responses to provisions that require Offeror completion of information, representations, and certifications (other than those collected via the System for Award Management (SAM)); and (6) A statement specifying the extent of agreement with all terms, conditions, and provisions included in the solicitation and any solicitation amendments. (b) Period for acceptance of offers. (Tailored) The Offeror agrees to hold the prices in its offer firm for 120 calendar days from the date specified for receipt of offers, unless another time period is specified in an addendum to the solicitation. (c) Late submissions, modifications, revisions, and withdrawals of offers. (1) Offerors are responsible for submitting offers and any modifications or revisions to the Government office designated in the solicitation by the time specified in the solicitation. (2) Any offer, modification, or revision received after the time specified for receipt of offers is “late” and will not be considered unless it is received before award is made and the Contracting Officer determines that accepting the late offer would not unduly delay the acquisition. However, a late modification of an otherwise successful offer that makes its terms more favorable to the Government will be considered at any time it is received and may be accepted. (3) If an emergency or unanticipated event interrupts normal Government processes so that offers cannot be received at the Government office designated for receipt of offers by the exact time specified in the solicitation, and urgent Government requirements preclude amendment of the solicitation or other notice of an extension of the closing date, the time specified for receipt of offers will be deemed to be extended to the same time of day specified in the solicitation on the first work day on which normal Government processes resume. (4) Offerors may withdraw their offers by written notice to the Government received at any time before award. (d) Contract award (not applicable to Invitation for Bids). The Government intends to evaluate offers and award a contract without discussions with Offerors. Therefore, the Offeror’s initial offer should contain the Offeror’s best terms. However, the Government reserves the right to conduct discussions, if necessary. The Government may reject any or all offers if such action is in the public interest, accept other than the lowest offer, and waive informalities and minor irregularities in offers received. (e) Debriefings. If a postaward debriefing is given to requesting Offerors, the Government will disclose the following information, if applicable: (1) The agency’s evaluation of the significant weak or deficient factors in the debriefed Offeror’s offer. (2) The overall evaluated cost or price and technical rating of the successful Offeror and the debriefed Offeror and past performance information on the debriefed Offeror. (3) The overall ranking of all Offerors when any ranking was developed by the agency during source selection. (4) A summary of the rationale for award. (5) For acquisitions of commercial products, the make and model of the product to be delivered by the successful Offeror. (6) Reasonable responses to relevant questions posed by the debriefed Offeror as to whether the agency followed source-selection procedures set forth in the solicitation, applicable regulations, and other applicable authorities. E.2 ADDENDUM to FAR 52.212-1 INSTRUCTIONS TO OFFERORS --COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES Instructions for Proposal Submission 1) Proposals will be accepted in Microsoft Word or PDF form via e-mail to [direct contact value redacted] at [direct contact value redacted] and [direct contact value redacted] with a scanned (pdf) copy of the signed SF-1449.  Please note that faxed proposals are not acceptable and will be rejected. Please note, zip files and folders are rejected by VA EPO servers, and emails with large attachments may not be received. VA suggests that offerors submit their proposals well before the deadline and confirm receipt of all attachments with the Contracting Officer listed on the SF-1449. Should an offeror submit multiple offerors, each offer will be evaluated individually. 2) Offerors shall include its Unique Entity Identifier and Contractor and Government Entity (CAGE) code in block 17a of the SF-1449. 3) For each item offered, offerors shall provide a separate and distinct 11-digit National Drug Code (NDC) Number unique to the offeror as outlined in the Scope of Contract (Section 8). 4) Offerors shall meet the packaging requirements as outlined in Scope of Contract (Section 5). 5) Offerors shall submit a price for all line items offered, inclusive of the base year and four option years. Offered prices must include 0.5% Cost Recovery Fee as outlined in the Scope of Contract (Section 12). 6) Offerors shall complete the solicitation representations at FAR 52.209-7 and FAR 52.219-1, as provided in Section E of the solicitation. 7) Country of Origin and VA’s interpretation of substantial transformation of pharmaceuticals. Offerors shall complete as applicable the certification at FAR 52.225-6. An article is a product of a country or instrumentality only if (i) it is wholly the growth, product, or manufacture of that country or instrumentality, or (ii) in the case of an article which consists in whole or in part of materials from another country or instrumentality, it has been substantially transformed into a new and different article of commerce with a name, character, or use distinct from that of the article or articles from which it was so transformed. See 19 U.S.C. § 2518(4)(B). For purposes of determining compliance with the Trade Agreements Act (TAA) (19 U.S.C. § 2512), the Government will evaluate the country of origin of offered pharmaceutical products to determine if the proposed products are U.S.-made or designated country end products (designated country is defined in FAR Part 25). Products in which final manufacturing occurs in the United States will be considered U.S.-made end products, regardless of the location of the active pharmaceutical ingredient (API) creation. Nonetheless, offerors of U.S.-made product shall disclose the API creation information requested in the solicitation’s Scope of Contract. For products manufactured outside the United States, the Government will evaluate the manufacturing processes performed and the location of these processes to determine whether the product was substantially transformed in a designated country on a case-by-case basis. When final manufacturing of single-API pharmaceuticals occurs outside the United States, the Government generally considers the country of origin to be determined by the location of API creation. Activities such as simple blending or mixing of inactive ingredients with the API, or compressing the mixture into a tablet or similar finished dosage form, will generally not be considered to constitute substantial transformation. For pharmaceuticals with multiple APIs, the Government typically interprets the country of origin as the location where final manufacturing occurs, as multiple APIs are combined, thus undergoing substantial transformation and resulting in a new product. However, because pharmaceutical manufacturing processes may vary, the Government reserves the right to evaluate the specific manufacturing process on a case-by-case basis to determine whether a substantial transformation has occurred. Note that at no time is product repackaging considered relevant to a pharmaceutical’s country of origin. Offerors shall provide sufficient supporting documentation with their proposal to substantiate the certified country of origin and the location of manufacturing processes relevant to the Government’s evaluation. Such documentation may include, but is not limited to, descriptions of the manufacturing processes, identification of manufacturing locations, and supporting statements from the manufacturer. In making its determination, the Government may consider relevant guidance and rulings issued by U.S. Customs and Border Protection regarding substantial transformation; however, the Government will not rely solely on such rulings. The Contracting Officer reserves the right to request additional information as necessary and will make the final determination regarding country of origin. Please reach out to the Contracting Officer specified in this solicitation for any questions concerning applicable or relevant information. Failure to provide adequate supporting documentation by the due date and time for offers or other deadlines specified by the Contracting Officer may result in the offerors’ products being determined to be end products of non-designated countries. 8) Subcontracting Plan Requirements: Pursuant to the requirements of Public Law 95-507 (15 U.S.C. § 644), all other than small business concerns are required to have an approved subcontracting plan for contracts valued over $900,000 before the Government can award a contract (see FAR 52.219-9 and VAAR 852.219-70 for details). Offerors must submit a currently approved commercial plan or a new plan for review and approval. Attachment “D” includes all of the elements required to be addressed and is included to facilitate the submission of a subcontracting plan. 9) SAM is the Official U.S. Government system for registering to do business with the federal government, completing company representations and certifications, listing contract opportunities, and more. Contractors/Offerors should go to http://www.sam.gov to find their information. Training tools are available on the SAM website for familiarization with the SAM system. Prospective contractors shall maintain an uninterrupted, current, and accurate record in the SAM database at the time of proposal submission, during evaluation, and during contract performance. SAM updates are required as necessary, but at least annually. Please indicate below the offeror’s SAM Unique Entity Identifier, DUNS number, and Tax ID Number (TIN) for SAM verification purposes: SAM Unique Entity Identifier:  _________________________ DUNS:                                    _________________________ TIN:                                    _________________________ 10) CONTRACTOR POINTS OF CONTACT Offerors shall indicate the individuals responsible for contract administration and for the submission of sales reports/Cost Recovery Fees. Contract Administration Point of Contact Name and Title ________________________________________________ Address ________________________________________________ City, State, Zip Code ________________________________________________ Email Address ________________________________________________ Phone Number ________________________________________________ Sales Report Point of Contact Name and Title ________________________________________________ Email Address ________________________________________________ Phone Number ________________________________________________ 11) AUTHORIZED NEGOTIATORS The offeror represents that the following persons are authorized to negotiate on its behalf with the Government in connection with this request for proposals: (list names, titles, e-mail addresses, and telephone numbers of the authorized negotiators) ____________________________________________________________________________ ____________________________________________________________________________ ____________________________________________________________________________ ____________________________________________________________________________ 12) NOTICE TO DEALERS AND SUPPLIERS (a) If the offeror is not the manufacturer of the offered items, the offeror shall submit: A Letter of Commitment from the manufacturer to the offeror which will assure the offeror of a source of supply sufficient to satisfy the Government's requirements for the contract period. Refer to the solicitation’s Continuation of Standard Form 1499: Schedule of Supplies/Services for the definition of “Manufacturer” for purposes of the Letter of Commitment and current Good Manufacturing Practices (cGMP) acceptability verifications. If the offeror and its manufacturer are affiliates, the Letter of Commitment or evidence as required herein is required of the manufacturing facility, regardless of the relationship with the offeror. The offeror must maintain the same manufacturer and NDA/ANDA/BLA for the duration of the contract period, unless the Contracting Officer makes a determination that a change in the manufacturer is acceptable. This determination may take place before or after contract award. If not a manufacturer, to be eligible for award, offerors must submit a Letter of Commitment that meets all requirements stated in section (b) below. (b) To be considered acceptable, the Letter of Commitment: Shall be on the manufacturer’s letterhead. Shall be dated. Shall reference the solicitation number and the product committed to the manufacture. Shall state that the manufacturer assures the offeror of an uninterrupted source of supply sufficient to satisfy the Government’s requirements for the contract period, and that the manufacturer is currently manufacturing the product. Shall disclose the country of API creation and the country of origin for the proposed products. Refer to FAR 52.225-5, FAR 52.225-6, and the language in Section 13 of the solicitation’s Scope of Contract and Section 7 of the solicitation’s Addendum to FAR 52.212-1 Instructions to Offerors – Commercial Products and Commercial Services for relevant information and definitions. Shall be signed by an officer of the manufacturer’s company (include printed name, title and telephone number). E.3 52.209-7 INFORMATION REGARDING RESPONSIBILITY MATTERS (VA DEVIATION NOV 2025) (a) Definitions. As used in this provision— Administrative proceeding means a non-judicial process that is adjudicatory in nature in order to make a determination of fault or liability (e.g., Securities and Exchange Commission Administrative Proceedings, Civilian Board of Contract Appeals Proceedings, and Armed Services Board of Contract Appeals Proceedings). This includes administrative proceedings at the Federal and State level but only in connection with performance of a Federal contract or grant. It does not include agency actions such as contract audits, site visits, corrective plans, or inspection of deliverables. Federal contracts and grants with total value greater than $10,000,000 means— (1) The total value of all current, active contracts and grants, including all priced options; and (2) The total value of all current, active orders including all priced options under indefinite-delivery, indefinite-quantity, 8(a), or requirements contracts (including task and delivery and multiple-award Schedules). Principal means an officer, director, owner, partner, or a person having primary management or supervisory responsibilities within a business entity (e.g., general manager; plant manager; head of a division or business segment; and similar positions). (b) The offeror [_] has [_] does not have current active Federal contracts and grants with total value greater than $10,000,000. (c) If the offeror checked "has" in paragraph (b) of this provision, the offeror represents, by submission of this offer, that the information it has entered in the Federal Awardee Performance and Integrity Information System (FAPIIS) is current, accurate, and complete as of the date of submission of this offer with regard to the following information: (1) Whether the offeror, and/or any of its principals, has or has not, within the last five years, in connection with the award to or performance by the offeror of a Federal contract or grant, been the subject of a proceeding, at the Federal or State level that resulted in any of the following dispositions: (i) In a criminal proceeding, a conviction. (ii) In a civil proceeding, a finding of fault and liability that results in the payment of a monetary fine, penalty, reimbursement, restitution, or damages of $5,000 or more. (iii) In an administrative proceeding, a finding of fault and liability that results in– (A) The payment of a monetary fine or penalty of $5,000 or more; or (B) The payment of a reimbursement, restitution, or damages in excess of $100,000. (iv) In a criminal, civil, or administrative proceeding, a disposition of the matter by consent or compromise with an acknowledgment of fault by the Contractor if the proceeding could have led to any of the outcomes specified in paragraphs (c)(1)(i), (c)(1)(ii), or (c)(1)(iii) of this provision. (2) If the offeror has been involved in the last five years in any of the occurrences listed in (c)(1) of this provision, whether the offeror has provided the requested information with regard to each occurrence. (d) The offeror shall post the information in paragraphs (c)(1)(i) through (c)(1)(iv) of this provision in FAPIIS as required through maintaining an active registration in the System for Award Management, which can be accessed via https://www.sam.gov (see 52.204-7). E.4 52.219-1 SMALL BUSINESS PROGRAM REPRESENTATIONS (VA DEVIATION NOV 2025) (a) Definitions. As used in this provision- Economically disadvantaged women-owned small business (EDWOSB) concern means a small business concern that is at least 51 percent directly and unconditionally owned by, and the management and daily business operations of which are controlled by, one or more women who are citizens of the United States and who are economically disadvantaged in accordance with 13 CFR part 127, and the concern is certified by SBA or an approved third-party certifier in accordance with 13 CFR 127.300. It automatically qualifies as a women-owned small business concern eligible under the WOSB Program. HUBZone small business concern means a small business concern that meets the requirements described in 13 CFR 126.200, is certified by the Small Business Administration (SBA) and designated by SBA as a HUBZone small business concern in the Small Business Search (SBS) ( 13 CFR 126.103). Service-disabled veteran-owned small business (SDVOSB) concern eligible under the SDVOSB Program means an SDVOSB concern that is designated in the System for Award Management (SAM) as certified by the Small Business Administration (SBA) in accordance with 13 CFR 128.300. Small business concern— (1) Means a concern, including its affiliates, that is independently owned and operated, not dominant in its field of operation, and qualified as a small business under the criteria in 13 CFR part 121 and the size standard in paragraph (b) of this provision. (2) Affiliates, as used in this definition, means business concerns, one of whom directly or indirectly controls or has the power to control the others, or a third party or parties control or have the power to control the others. In determining whether affiliation exists, consideration is given to all appropriate factors including common ownership, common management, and contractual relationships. SBA determines affiliation based on the factors set forth at 13 CFR 121.103. Small disadvantaged business concern means a small business concern that- (1) Is at least 51 percent unconditionally and directly owned (as defined at 13 CFR 124.105) by one or more socially disadvantaged (as defined at 13 CFR 124.103) and economically disadvantaged (as defined at 13 CFR 124.104) individuals who are citizens of the United States, and (2) The management and daily business operations of which are controlled (as defined at 13 CFR 124.106) by individuals who meet the criteria in paragraph (1) of this definition. Women-owned small business (WOSB) concern eligible under the WOSB Program (in accordance with 13 CFR part 127) means a small business concern that is at least 51 percent directly and unconditionally owned by, and the management and daily business operations of which are controlled by, one or more women who are citizens of the United States, and the concern is certified by SBA or an approved third-party certifier in accordance with 13 CFR 127.300. (b) (1) The North American Industry Classification System (NAICS) code for this acquisition is 325412. (2) The small business size standard is 1,300 employees. (3) The small business size standard for a concern that submits an offer, other than on a construction or service acquisition, but proposes to furnish an end item that it did not itself manufacture, process, or produce (i.e., nonmanufacturer), is 500 employees, or 150 employees for information technology value-added resellers under NAICS code 541519, if the acquisition— (i) Is set aside for small business and has a value above the simplified acquisition threshold; (ii) Uses the HUBZone price evaluation preference regardless of dollar value, unless the offeror waives the price evaluation preference; or (iii) Is an 8(a), HUBZone, service-disabled veteran-owned, economically disadvantaged women-owned, or women-owned small business set-aside or sole-source award regardless of dollar value. (c) Representations. (1) The offeror represents as part of its offer that— (i) it □ is, □ is not a small business concern; or (ii) It □ is, □ is not a small business joint venture that complies with the requirements of 13 CFR 121.103(h) and 13 CFR 125.8(a) and (b). [ The offeror shall enter the name and unique entity identifier of each party to the joint venture: __.] (2) [Complete only if the offeror represented itself as a small business concern in paragraph (c)(1) of this provision.] The offeror represents that it □ is, □ is not a women-owned small disadvantage business concern. (3) Women-owned small business (WOSB) joint venture eligible under the WOSB Program. The offeror represents as part of its offer that it □ is, □ is not a joint venture that complies with the requirements of 13 CFR 127.506(a) through (c). [ The offeror shall enter the name and unique entity identifier of each party to the joint venture: __.] (4) Economically disadvantaged women-owned small business (EDWOSB) joint venture. The offeror represents as part of its offer that it □ is, □ is not a joint venture that complies with the requirements of 13 CFR 127.506(a) through (c). [ The offeror shall enter the name and unique entity identifier of each party to the joint venture: __.] (5) SDVOSB joint venture eligible under the SDVOSB Program. [Complete only if the offeror is certified as a SDVOSB concern]. The offeror represents as part of its offer that it □ is, □ is not a SDVOSB joint venture eligible under the SDVOSB Program that complies with the requirements of 13 CFR 128.402. [ The offeror shall enter the name and unique entity identifier of each party to the joint venture:__.] (6) HUBZone joint venture eligible under the HUBZone Program. [Complete only if the offeror is a HUBZone small business concern.] The offeror represents, as part of its offer, that it □ is, □ is not a HUBZone joint venture that complies with the requirements of 13 CFR 126.616(a) through (c). [ The offeror shall enter the name and unique entity identifier of each party to the joint venture: __.] Each HUBZone small business concern participating in the HUBZone joint venture must be certified as a HUBZone concern. (d) Notice. Under 15 U.S.C. 645(d), any person who misrepresents a firm’s status as a business concern that is small, HUBZone small, small disadvantaged, service-disabled veteran-owned small, economically disadvantaged women-owned small, or women-owned small eligible under the WOSB Program in order to obtain a contract to be awarded under the preference programs established pursuant to section 8, 9, 15, 31, and 36 of the Small Business Act or any other provision of Federal law that specifically references section 8(d) for a definition of program eligibility, will be— (1) Punished by imposition of fine, imprisonment, or both; (2) Subject to administrative remedies, including suspension and debarment; and (3) Ineligible for participation in programs conducted under the authority of the Act. E.5 52.225-6 TRADE AGREEMENTS CERTIFICATE (FEB 2021) (a) The offeror certifies that each end product, except those listed in paragraph (b) of this provision, is a U.S.-made or designated country end product, as defined in the clause of this solicitation entitled "Trade Agreements." (b) The offeror shall list as other end products those end products that are not U.S.-made or designated country end products. Other End Products: Line Item No. | Country of Origin _______________ | __________________ _______________ | __________________ ______________ | __________________ [List as necessary] (c) The Government will evaluate offers in accordance with the policies and procedures of part 25 of the Federal Acquisition Regulation. For line items covered by the WTO GPA, the Government will evaluate offers of U.S.-made or designated country end products without regard to the restrictions of the Buy American statute. The Government will consider for award only offers of U.S.-made or designated country end products unless the Contracting Officer determines that there are no offers for such products or that the offers for such products are insufficient to fulfill the requirements of the solicitation. E.6 52.216-1 TYPE OF CONTRACT (VA DEVIATION NOV 2025) The Government contemplates award of a Firm Fixed Price, Indefinite-Delivery Requirements contract resulting from this solicitation. E.7 52.233-2 SERVICE OF PROTEST (VA DEVIATION NOV 2025) (a) Protests, (as defined in FAR 33.102), that are filed directly with an agency, and copies of any protests that are filed with the Government Accountability Office (GAO), must be served on the Contracting Officer identified in the solicitation by obtaining written and dated acknowledgment of receipt from them. Email Addresses: [direct contact value redacted] [direct contact value redacted] [direct contact value redacted] [direct contact value redacted] (b) The copy of any protest must be received in the office designated above within one day of filing a protest with the GAO. E.8 52.212-2 EVALUATION—COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES (VA DEVIATION NOV 2025) A contract will be awarded to the responsible offeror that submits an offer meeting the solicitation requirements, and is the lowest price technically acceptable offer. An offer will be considered to be technically acceptable if it meets all the following criteria: The offered items must fully meet the product description, to include, the drug name, strength(s), and package size(s), as stated in the Schedule of Supplies. The National Drug Code (NDC) number of each offered product must be unique to the offeror. All offered pharmaceuticals must be Food and Drug Administration (FDA) approved. The FDA approval(s) must be verifiable by the Contracting Officer. All places of performance identified in the Scope of Contract, Section 13.7, must be FDA cGMP Acceptable for the product type offered. The FDA cGMP Acceptable status(es) must be verifiable by the Contracting Officer. The manufacturing facility must have clearance by the FDA to manufacture under the specific NDA/ANDA/BLA cited/used in the offer. The FDA clearance(s) must be verifiable by the Contracting Officer. One award will be made in the aggregate for line items 1, 2, and 3 including the base year and all four option years. In order to be considered for award, the offeror shall submit a price for line items 1, 2, and 3 for the base year and all four option years. Proposals that fail to include a price for the base year and each of the four option years for line items 1, 2, and 3 may be rejected and receive no further consideration. Offered prices shall include the 0.5% Cost Recovery Fee (see Scope of Contract, Section 12). The price evaluation will be computed by multiplying the estimated quantity of the line item by the unit prices offered for the base year and option years and adding the results of all line items. Unit prices offered shall not exceed two decimal places. The Government intends to evaluate offers and award a contract without discussions with offerors. However, the Government reserves the right to conduct discussions if determined by the Contracting Officer to be necessary. The Government will evaluate offers in accordance with the policies and procedures of the FAR Part 12, Part 15, and Part 25. An award will be made on the basis of the lowest evaluated price of proposals meeting or exceeding the acceptability standards for non-cost factors. Past Performance will be evaluated to determine contractor responsibility in accordance with FAR Part 9. Options. The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the base requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s). A written notice of award or acceptance of an offer emailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer’s specified expiration time, the Government may accept an offer, whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. E.9 52.252-1 SOLICITATION PROVISIONS INCORPORATED BY REFERENCE (FEB 1998) This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at this/these address(es): https://www.acquisition.gov/content/far-index https://www.va.gov/oal/library/vaar/ FAR/VAAR Provision | Title | Date 52.203-11 | CERTIFICATION AND DISCLOSURE REGARDING PAYMENTS TO INFLUENCE CERTAIN FEDERAL TRANSACTIONS | SEPT 2024 52.203-18 | PROHIBITION ON CONTRACTING WITH ENTITIES THAT REQUIRE CERTAIN INTERNAL CONFIDENTIALITY AGREEMENTS OR STATEMENTS-REPRESENTATION | JAN 2017 52.204-7 | SYSTEM FOR AWARD MANAGEMENT | VA DEVIATION NOV 2025 52.214-34 | SUBMISSION OF OFFERS IN THE ENGLISH LANGUAGE | APR 1991 52.214-35 | SUBMISSION OF OFFERS IN U.S. CURRENCY | APR 1991 52.219-4 | NOTICE OF PRICE EVALUATION PREFERENCE FOR HUBZONE SMALL BUSINESS CONCERNS | VA DEVIATION NOV 2025 52.240-90 | SECURITY PROHIBITIONS AND EXCLUSIONS REPRESENTATIONS AND CERTIFICATIONS | VA DEVIATION NOV 2025 852.209-70 | ORGANIZATIONAL CONFLICTS OF INTEREST | OCT 2020 852.215-72 | NOTICE OF INTENT TO RE-SOLICIT | OCT 2019 852.233-70 | PROTEST CONTENT/ALTERNATIVE DISPUTE RESOLUTION | SEP 2018 852.233-71 | ALTERNATE PROTEST PROCEDURE | SEP 2018 E.10 52.252-5 AUTHORIZED DEVIATIONS IN PROVISIONS (NOV 2020) (a) The use in this solicitation of any Federal Acquisition Regulation (48 CFR chapter 1) provision with an authorized deviation is indicated by the addition of “(DEVIATION)” after the date of the provision. (b) The use in this solicitation of any Department of Veterans Affairs Acquisition Regulation System (48 CFR chapter 8) provision with an authorized deviation is indicated by the addition of “(DEVIATION)” after the name of the regulation.

Official source: SAM.gov ↗

Notice updates

October 16, 2026 · Version 2

Buyer updated · Classification updated · Deadline information updated · Summary and analysis updated · Tender facts updated · Original notice updated · Deadline updated · Location updated · Source updated · Source notice details updated · Source references updated · Status changed · Notice update added

6505--Prednisolone 1% Ophthalmic Solution

Continuation of SF-1449, Block 3: The following information shall be entered by the Contracting Officer at the time of contract award according to the timeframes specified in this solicitation’s Section B, Scope of Contract, Section 1.4 Contract Effective Date, Implementation Period, and Ordering Period. Contract Award/Effective Date: ___________________ Implementation Period: __________________________ Ordering Period (Base Year): _____________________ Offerors shall not enter information into the above fields. Continuation of SF-1449, Blocks 19 through 24: Line items 1 - 3 To be considered for award, offerors must submit a price for line items 1, 2, and 3 for the base year and all four option years. One award will be made in the aggregate for line items 1, 2, and 3 for the base year and all four option years. Offered prices shall not exceed two decimal places. Note: NDC is defined as National Drug Code. ANDA is defined as Abbreviated New Drug Application. Line Item 1 Prednisolone Acetate 1% Ophthalmic Suspension 5ML NDC # __________________ ANDA#_________________ Schedule of Supplies | Quantity | Unit | Unit Price | Amount (Unit Price x Quantity) Base Year | 392,107 | Bottles | Option Year One | 392,107 | Bottles | Option Year Two | 392,107 | Bottles | Option Year Three | 392,107 | Bottles | Option Year Four | 392,107 | Bottles | Line Item 2 Prednisolone Acetate 1% Ophthalmic Suspension 10ML NDC # __________________ ANDA#_________________ Schedule of Supplies | Quantity | Unit | Unit Price | Amount (Unit Price x Quantity) Base Year | 70,070 | Bottles | Option Year One | 70,070 | Bottles | Option Year Two | 70,070 | Bottles | Option Year Three | 70,070 | Bottles | Option Year Four | 70,070 | Bottles | Line Item 3 Prednisolone Acetate 1% Ophthalmic Suspension 15ML NDC # __________________ ANDA#_________________ Schedule of Supplies | Quantity | Unit | Unit Price | Amount (Unit Price x Quantity) Base Year | 10,172 | Bottles | Option Year One | 10,172 | Bottles | Option Year Two | 10,172 | Bottles | Option Year Three | 10,172 | Bottles | Option Year Four | 10,172 | Bottles | SECTION B - CONTINUATION OF SF-1449 BLOCKS CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES Please be advised, the following paragraphs are also included elsewhere in the solicitation, but are included here for offeror reference. Proposals will be accepted in Microsoft Word or PDF format via e-mail at [direct contact value redacted] and [direct contact value redacted] with a scanned (pdf) copy of the signed SF-1449. Please note that faxed proposals are not acceptable and will be rejected. Please note, zip files and folders are rejected by the Department of Veterans Affairs (VA) Enterprise Procurement Office (EPO) servers, and emails with large attachments may not be received. VA suggests that offerors submit their proposals well before the deadline and confirm receipt of all attachments with the Contracting Officer listed on the SF-1449. If the offeror is not the manufacturer of the offered items, the offeror shall submit a Letter of Commitment from the manufacturer to the offeror which will assure the offeror of a source of supply sufficient to satisfy the Government's requirements for the contract period. For the purposes of the Letter of Commitment and current Good Manufacturing Practices (cGMP) acceptability verifications (refer to the solicitation’s Scope of Contract for cGMP details), “Manufacturer” is defined as the entity which is engaged in the production, preparation, propagation, compounding, conversion, or processing of active and inactive ingredients to form drug products, whether directly or indirectly by extraction from substances of natural origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis. This process includes the measuring, mixing, weighing, and compounding both the active and inactive ingredients. The product is then converted into various drug forms, suitable for administration through tablets, capsules, liquids (in the form of solutions, suspensions, emulsions, gels, or injectables), creams, ointments, or aerosols. An acceptable Letter of Commitment is required from all distributor-offerors to be eligible for award. The offeror must maintain the same manufacturer and New Drug Application (NDA)/Abbreviated New Drug Application (ANDA)/Biologics License Application (BLA) for the duration of the contract period, unless the Contracting Officer makes a determination that a change in the manufacturer is acceptable. This determination may take place before or after contract award. If the offeror is not a manufacturer, to be eligible for award, offerors must submit a Letter of Commitment that meets all requirements stated in the Addendum to FAR 52.212-1 Instructions to Offerors-Commercial Products and Commercial Services. One award will be made in the aggregate for all line items for the base year, including all four option years. To be considered for award, offerors must propose a price for line items 1, 2, and 3 for the base year and each option year. Proposals that fail to include a price for the base year and each of the four option years for line items 1, 2, and 3 may be rejected and receive no further consideration. (Refer to Schedule of Supplies for package size details and estimates) Offered prices shall include a 0.50% Cost Recovery Fee (See Scope of Contract, Section 12). The Government will evaluate offers in accordance with the policies and procedures of the FAR Part 12, Part 15, and Part 25. Acknowledgement of Amendments. The following amendments are acknowledged as part of this solicitation. (Please complete if applicable) Amendment Number | Date Acknowledged by Offeror The System for Award Management (SAM) is the Official U.S. Government system for registering to do business with the federal government, completing company representations and certifications, listing contract opportunities, and more. Contractors/Offerors should go to http://www.sam.gov to find their information. Training tools are available on the SAM website for familiarization with the SAM system. Prospective contractors shall maintain an uninterrupted, current, and accurate record in the SAM database at the time of proposal submission, during evaluation, and during contract performance. SAM updates are required as necessary, but at least annually. System updates may lag policy updates. The System for Award Management (SAM) may continue to require entities to complete representations based on provisions that are not included in this solicitation. Contracting officers will rely on representations from offers based on provisions in the solicitation. Entities are not required to, nor are they able to, update their entity registration to remove these representations in SAM. Subcontracting Plan Requirements: Pursuant to the requirements of 15 U.S.C. § 644, all other than small business concerns are required to have an approved subcontracting plan for contracts valued over $900,000 before the Government can award a contract (see FAR 52.219-9 and VAAR 852.219-70 for details). Offerors must submit a currently approved commercial plan or a new plan for review and approval. Attachment “D” includes all of the elements required to be addressed and is included to facilitate the submission of a subcontracting plan. As prescribed in FAR Subpart 42.11, the Department of Veterans Affairs (VA) evaluates contractor performance on all contracts that exceed the Simplified Acquisition Threshold and shares those evaluations with other federal government agencies. The FAR requires that the contractor be provided an opportunity to comment on past performance evaluations prior to each report closing. To fulfill this requirement, VA will be using an online database, the Contractor Performance Assessment Reporting System (CPARS). Annual reporting of past performance will be completed at http://www.cpars.gov. SCOPE OF CONTRACT 1. INTRODUCTION 1.1 Background. All Ordering Activities under the VA and all Ordering Activities under the Department of Defense (DoD) acquire their pharmaceutical requirements through their respective Pharmaceutical Prime Vendor (PPV) Programs, hereafter referred to as the VA PPV Program and DoD PPV Program or jointly as PPV Programs. The PPV Programs are separate contracts which establish the fees for the distribution of pharmaceutical products that are distributed through the PPV Programs on Federal Government (i.e., Federal Supply Schedules, National Standardization) contracts. A contract resulting from this solicitation establishes the VA National Contract prices for the products listed in the schedule of supplies that will be distributed through the PPV Programs. Section 2.1, “Government Participants” lists the PPV Program participants that will be authorized users of the contract resulting from this solicitation. 1.2 Purpose and Objectives. The purpose of this solicitation is to establish a supply source that will provide the drugs listed in the schedule for purchase through the PPV Programs. The total annual estimated usage for VA, Federal Health Care Center (FHCC), State Veterans Homes (SVH) - Option 2, DoD, Indian Health Service (IHS), and Bureau of Prisons (BOP) appears on the Schedule of Supplies section of this Solicitation. The objective of such a contract is to ensure availability and consistency of product for nationwide usage and to obtain volume-based, committed-use pricing. 1.3 Government Purchase Compliance. VA, FHCC, SVH (Option 2), DoD, IHS, and BOP will purchase their requirements for the strengths of the drugs listed in the schedule through the PPV Programs except when: (1) the contracted items are unavailable to meet the needs of the Government, or (2) an alternate is requested by the prescribing healthcare provider, or (3) additionally, IHS will not participate if the awardee does not have a Centers of Medicare or Medicaid (CMS) reimbursable product(s). In the event that exception 1, 2, or 3 applies, these instances will be considered exceptions to FAR 52.216-21, Requirements. VA’s PPV contract has ordering lock-out procedures in place to support VA contract compliance and to prevent purchases of non-contract products. Participants of the VA PPV Program include VA, FHCC, SVH (Option 2), IHS, and BOP. DoD manages compliance through individual facility tracking reports. Contract Effective Date, Implementation Period, and Ordering Period. (A) Contract Effective Date. The contract will be effective on the date the Contracting Officer signs the SF-1449 and notifies the offeror (contractor) of award. (B) Implementation Period. The timeframe beginning on the Contract Effective Date and ending at the start of the Ordering Period in which PPVs begin placing orders with the contractor for delivery to the multiple PPV distribution centers is the Implementation Period. Contractors will be allowed a maximum of a 60-day Implementation Period (but may be shorter than 60 calendar days if mutually agreed between the contractor and the Government), if the contract is awarded after February 28, 2027. If the contract is awarded prior to February 28, 2027, the Implementation Period will begin when the contract is awarded and end on April 30, 2027. There are approximately 31 VA PPV Distribution Centers and approximately 25 DoD PPV Distribution Centers located nationwide. The contractor shall ensure that sufficient inventory of contract items awarded under this solicitation is available, and that chargeback agreements with the PPVs have been executed with sufficient time to permit the PPVs to begin timely distribution of Government orders by the expiration of the contract Implementation Period. The current PPVs are listed as attachments “A” and “B” of this solicitation. The current PPVs may change and the contractor will be notified of any changes in PPV contractors during the term of the contract resulting from this solicitation. Payment terms, time and place of delivery to PPV distribution centers, and other business-to-business agreement terms shall be agreed upon between the PPV contractors and the contractor awarded a contract from this solicitation. While it is a requirement that the contractor establish a business-to-business agreement with the PPVs, the Government is not a party to this business-to-business agreement and does not negotiate for either the Contractor or PPVs. The Contracting Officer shall be notified by the contractor if any business-to-business-agreements cannot be reached with the PPVs by 15 calendar days before commencement of the Ordering Period. Failure or refusal to reach agreement with the PPVs and maintain an agreement with the PPVs throughout the entire contract period shall constitute sufficient cause for terminating the contract under FAR 52.212-4(m), Contract Terms and Conditions-Commercial Products and Commercial Services, Termination for Cause. (C) Ordering Period. The Ordering Period begins at the expiration of the Implementation Period. The base year Ordering Period will be in effect for the period of one (1) year. During this period, Government participants place orders with the PPVs, who ship product to the Government participants. The PPVs shall order product from the Contractor and the Contractor shall ship to the PPVs in accordance with the terms of the Contractor and PPV business-to-business agreements. Failure to provide awarded product meeting all solicitation/contract requirements by the ordering period start date may result in contract termination in accordance with FAR 52.212-4(m), Contract Terms and Conditions-Commercial Products and Commercial Services, Termination for Cause. (D) At the time of contract award, the Contracting Officer shall indicate the contract Effective Date, Implementation Period, and Ordering Period on Page 2 of the SF-1449, in accordance with the timeframes specified in this section. 1.5 Contract Duration. The contract resulting hereunder will be in effect for the duration of the Implementation Period described in Section 1.4 plus one (1) year Ordering Period with four (4) one (1) year pre-priced option (ordering) periods that may be exercised unilaterally by the Government in accordance with FAR 17.204-1 and FAR 52.217-9. 1.6 Special Contract Considerations. As discussed in Section 1.2, this solicitation establishes a supply source to provide the drugs listed in the schedule for purchase through the PPV programs. Additionally, as outlined in Section 1.4, the awarded offeror (contractor) under this solicitation must reach and maintain a business-to-business agreement with the respective PPV programs for the duration of the contract. Because the PPV programs distribute the supplies sourced from this solicitation, special contract considerations apply. Under this resulting contract, the contractor will be receiving payments from the PPV programs instead of directly from the Government. Due to this unique payment structure, contractors are not permitted to assign their rights to receive payment under this contract. Additionally, disputes arising between a contractor and any authorized Government Prime Vendor(s) do not give rise to a “claim” under the Disputes Clause. Finally, no invoices will be provided from the contractor to the Government ordering facilities. Instead, the contractor shall submit invoices in accordance with the business-to-business agreements reached with the PPV programs. 2. EXTENT OF OBLIGATION 2.1 Government Participants. The contractor shall provide the products specified in the schedule at the prices awarded herein for the facilities/agencies below: All Department of Veterans Affairs (VA) facilities All Ordering Activities under the Department of Defense (DoD) Pharmaceutical Prime Vendor Program All Indian Health Service (IHS) facilities All Bureau of Prisons (BOP) facilities Captain James A. Lovell Federal Health Care Center (FHCC) All Option 2 State Veteran Homes (See Section 2.2 State Veteran Homes) A database of all facilities authorized to use the VA PPV Program may be downloaded from the Enterprise Procurement Office’s web site at http://www.va.gov/oal/business/nc/ppv.asp. 2.2 State Veteran Homes (SVHs). There are numerous SVHs that have entered into sharing agreements with VA Medical Centers (VAMCs). The SVHs with sharing agreements that participate in the VA PPV Program are identified as being one of two types: Option 1 or Option 2. Option 1: The SVH orders pharmaceuticals directly from the VA PPV and pays the VA PPV for all items purchased. An Option 1 SVH is not eligible for national contract prices awarded under this solicitation unless it is specifically named in the scope of contract or added after award by mutual agreement between the contractor and the Government. Option 2: The VAMC authorizes the SVH’s order, and the VAMC makes payment to the VA PPV for all pharmaceuticals ordered by the SVH. An Option 2 SVH is eligible for the national contract prices awarded under this solicitation. 2.3 Consolidated Mail Outpatient Pharmacies (CMOPs) (VA ONLY) and Tricare Mail Order Pharmacies (TMOPs) (DoD ONLY). Many drugs are prescribed and mailed directly to patients’ homes in three-month or 90-day supply and VA CMOPs/DoD TMOPs may place an initial order with the VA PPV/DoD PPV contractor for up to 30% of the estimated VA/DoD annual contract quantities immediately upon the commencement of the ordering period. An initial order of up to 30% of the estimated VA/DoD annual contract quantities may be placed by the VA PPV/DoD PPV contractor with the contractor awarded a contract under this solicitation to fulfill the CMOP and/or TMOP 30% initial order requirements. 2.4 Estimated Quantities. The quantities in the schedule reflect the combined usage of all VA (inclusive of FHCC and Option 2 SVH), DoD, IHS, and BOP activities currently participating in the PPV Programs. These estimated annual requirements do not include those of any other Government agency, including those currently participating in the VA PPV Program (e.g. Immigration and Customs Enforcement, Option 1 State Veteran’s Homes). The estimated usage cited in the Schedule is the Government’s total estimated usage for the strengths listed. There is no expressed or implied guarantee that the estimated quantity will be purchased under this contract. Actual quantities purchased may exceed or be less than those represented. 3. PRODUCT REGISTRATION Product information pertaining to all items offered under this solicitation, including the offeror’s unique National Drug Code(s) (NDC), must be submitted for registration to the Food and Drug Administration (FDA), First Databank, Oracle Cerner/Multum (Multum), and Medispan no later than five calendar days after notification of contract award. The awarded contractor shall notify the Contracting Officer if there are any issues delaying registration. A New Product Submission Form can be obtained by contacting First Databank at [direct contact value redacted], extension 566, or information can be obtained at http://www.fdbhealth.com/solutions/manufacturer-relations/. Multum information can be obtained and submitted at [direct contact value redacted]. Further information on the Oracle/Multum database is available at https://www.nlm.nih.gov/research/umls/rxnorm/sourcereleasedocs/mmsl.html. Medispan information can be obtained at https://www.wolterskluwer.com/en/solutions/medi-span. 4. NATIONAL CONTRACT ITEM BACKORDERS A contract awarded under this solicitation will be the Government’s primary source of supply (See FAR 52.216-21 Requirements). The Government’s ability to provide quality healthcare to its patient population is severely impaired when a national contract product is not available due to backorders. The purpose of this paragraph is to provide guidance to the awarded offeror (contractor) regarding a temporary solution to national contract item backorders that may be implemented in lieu of the Government terminating the contract for cause. However, consideration of this paragraph shall not waive any of the Government’s rights to terminate the contract for cause in accordance with FAR 52.212-4(m) Termination for Cause. For purposes of this contract, a backorder occurs when the PPVs issue an order with the contractor, and the complete order quantity is not delivered to the PPVs within 15 calendar days after receipt of order. This includes initial CMOP orders. If a national contract item is backordered by the PPVs, the Contracting Officer will investigate the backorder to determine if the national contract contractor bears responsibility for the backorder. The awarded contractor shall inform the Contracting Officer within four calendar days after a backorder occurs. In addition to informing the Contracting Officer of the backorder, the contractor shall provide an estimated date when the backorder will be shipped, and may propose a solution to satisfy the Government’s needs for the contract items until the backorder is resolved. The Government reserves the right to accept or reject any possible solutions that the contractor may propose to alleviate a national contract backorder situation. If the contracting officer determines that the contractor bears responsibility for the backorder, and the contractor is not able to provide a solution that is acceptable to the Government, (i.e., acceptable solution to the backorder, in lieu of Termination for Cause), the parties agree that the Government may buy against the contractor by acquiring the same or similar items from another source and billing the contractor for any excess procurement costs. In other words, if the Government must purchase product from another vendor because of a national contract backorder, the contractor will issue credit or reimburse the Government for the difference between the purchase price and the contract price within 30 calendar days after receipt of notification. The contractor shall also provide written verification to the Contracting Officer when credits or reimbursement have been made within 30 calendar days from date of reimbursement. After a backorder incident occurs for which the contractor is responsible, the Government’s decision to enter into a buy-against agreement described above will not deprive the Government of its right under FAR 52.212-4(m) to terminate the contract for a breach of the buy-against agreement, for a subsequent contractor-caused backorder, or for any other sufficient cause. 5. PACKAGING REQUIREMENTS Offerors must state the exact name and strength of the drug being supplied as it will appear on the label. Offerors shall also provide a unique 11-digit NDC number for all items offered; the NDC number must be specific to the offering company and to the drug being supplied. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. VA labels must be able to securely adhere on top of the successful offeror/contractor’s label. Glass bottles are not acceptable. All bottles must be compatible with automated dispensing units (Baxter ATC Canisters, Optifill, etc.). Items are identified in the Schedule of Supplies and in Attachment C. By submitting an offer in response to this solicitation, the offeror certifies that all offered products have passed any required stability testing for all proposed package sizes. 6. BAR CODING All pharmaceutical products provided under this contract shall include bar code labeling at the unit-of-use package level. The bar code labeling must be in a linear format that conforms to all GS1-128 (formerly EAN.UCC) or Health Industry Business Communication Council (HIBCC) Health Industry Bar Code (HIBC) supplier labeling standards. The bar code symbology must comply with all GS1 or HIBCC HIBC parameters including, but not limited to: symbology type or encoded pattern, bar and space dimensions and tolerances, and allowable ratio of wide to narrow elements. The bar code may be any linear bar code symbology such as GS1-128 (formerly EAN.UCC), GS1 DataBar (formerly RSS), or Universal Product Code (UPC) (if the UPC contains the National Drug Code or NDC). The bar code must encode the NDC, either alone or within the GS1 data structure (Global Trade Item Number (GTIN). The bar code printing must be American National Standards Institute (ANSI)/International Organization for Standardization (ISO)/IEC Quality Grade C or better. Manufacturers and packagers must ensure that production runs include an initial verification check, as well as routine audits to ensure the bar code is printed clearly and consistently to meet the quality standard of Grade C or better. Contractors shall be responsible for ensuring that bar code labels meet the quality requirements specified in this section prior to shipping pharmaceutical products to any Government Prime Vendor under this contract. The bar code must be on the outside container or wrapper of the medication as well as on the immediate container, unless the bar code is readily visible and machine-readable through the outside container or wrapper. When the bar code is not easily machine-readable through the over wrap, the over wrap must contain the bar code. If applicable, the bar code must go on each cell of a blister pack. Furthermore, the bar code must remain intact under normal conditions of use; thus it should not be printed across the perforations of a blister pack. When applicable to the symbology used, bar codes shall be surrounded by sufficient quiet zone so that the bar code can be scanned correctly. Bar code placement shall minimize curvature of the bar code. For example, bar codes should be placed in “ladder orientation” on vials or bottles to minimize curvature of the bar code. Bar code labeling shall not be placed solely on outer packaging. The Drug Supply Chain Security Act (DSCSA) now requires a two-dimensional data matrix bar code (GS-1 data matrix bar code preferred) for each product down to the lowest saleable package size (see Section 7, below, for additional DSCSA requirements); however, the FDA bar code rule for linear bar codes still applies to all packaging as stated above. A human readable number must be placed adjacent (preferably below) the encoded bar code to ensure product is usable with VA Bar Code Medication Administration (BCMA) in the event the bar code is in some way damaged. It is recommended that bar code labeling also include the lot number and expiration date. If two separate distinctive bar codes are used, one for NDC and the other for lot number/expiration date; the lot number and expiration date bar code must not be in close proximity to the NDC barcode or in a format that may be confused with the NDC bar code. When applicable, all Healthcare Distribution Alliance (HDA) guidelines (formerly HDMA) shall be followed. 7. DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) REQUIREMENTS Title II of the Drug Quality and Security Act (DQSA), known as the DSCSA, applies to all drug products, with the exception of those listed on the DSCSA exemption list: Title II of the Drug Quality and Security Act | FDA. As part of the requirement of the DSCSA, drug products are required to provide serialized DSCSA Transaction Information and Transaction Statements using GS1 industry standard Electronic Product Code Information Services (EPCIS) files following the GS1 US Implementation Guideline: The GS1 US DSCSA Implementation Suite (gatewaychecker.com) in order to transmit the files needed for tracking. DSCSA also requires that all trading partners of manufacturers, wholesale distributors, dispensers, and repackagers meet applicable requirements for being authorized trading partners. The National Association of Boards of Pharmacy (NABP) has established a trading partner directory, which is a repository of authorized trading partners that can be accessed to authenticate authorized trading partners in real time. All VA and other participating agency pharmacies will be entered in this directory as authorized trading partners using unique identifiers. Current and prospective trading partners of the VA other participating agencies are required to complete a registration prior to selling pharmaceuticals to these agencies. Neither the Government, nor the vendors will be charged a fee to participate in the directory. DSCSA drug products are required to provide the serialized DSCSA Transaction Information and Transaction Statement required for the interoperable electronic DSCSA system using GS1 industry standard EPCIS files following the GS1 US Implementation Guideline. Suppliers establishing an EPCIS connection for DSCSA will need to inform their trading partners of the master data for the Global Trade Item Number (GTIN) and Global Location Numbers (GLNs) that they utilize. These are necessary to establish the EPCIS connection in addition to being able to transmit the file using AS2 or another method. This onboarding must be complete as product may not be purchased or sold without the serial DSCSA Transaction Information. Registration and valid status in the National Association of Boards of Pharmacy (NABP) Trading Partner Directory is required also for all VA contract holders pursuant to DSCSA. 8. NATIONAL DRUG CODES Offerors shall provide a separate and distinct 11-digit NDC Number unique to the offeror (e.g., 00012-3456-78) for each product proposed, in the space provided following each item in block 20 of the SF-1449, “Schedule of Supplies and Prices” of the solicitation. The first five numbers of the 11-digit NDC number for each product proposed shall identify the offeror. Offerors must provide their own labeler code, to be used in the NDC number for the offered items. If an offeror is a dealer/distributor and does not have a labeler code, it must apply and be approved with the FDA for its own labeler code prior to making an offer under this solicitation. Offers that fail to provide the information required by this paragraph by the solicitation’s due date and time for receipt of offers may be rejected and receive no further consideration. 9. DRUG APPLICATION By signing this solicitation, the offeror certifies that it has on file (if any of the following are required by the FDA for the offered drugs): an FDA approved New Drug Application (NDA), an approved abbreviated NDA (ANDA), or an approved Biologics License Application (BLA), as appropriate for the items offered in response to the solicitation. 10. RECALLS If a drug recall is initiated for any drug provided under this contract, regardless of whether it is a voluntary recall by the manufacturer or a recall required by the FDA; or, if FDA withdraws its approval to manufacture any drug that is included on this contract, the contractor shall immediately forward the recall notification, along with any pertinent information via email to the assigned Contracting Officer and to the following: [direct contact value redacted] Chief, Pharmaceutical Division, Acquisition Service 7 VA Enterprise Procurement Office 1st Ave., 1 Block North of Cermak Rd., Bldg. 37 P.O. Box 76, Hines, IL 60141 [direct contact value redacted] Deputy Chief Consultant (M/S119D) VHA Pharmacy Benefits Management Services 1st Ave., 1 Block North of Cermak Rd., Bldg. 37, Rm 139 Hines, IL 60141 [direct contact value redacted] Manager, Product Recall Office National Center for Patient Safety Veterans Health Administration 24 Frank Lloyd Wright Drive, Lobby M Ann Arbor, MI 48106 [direct contact value redacted] Phone Number: [direct contact value redacted] All Government Prime Vendors that were sent shipments of the affected product(s) shall also be provided a copy of the recall notification along with any pertinent information. 11. COVERED DRUGS Should a covered drug (as defined in 38 U.S.C. § 8126(h)(2)) be proposed and awarded as a result of this solicitation, the awarded prices shall meet the requirements of 38 U.S.C. § 8126 and shall apply to all Government participants listed in Section 2.1 of the Scope of Contract, regardless of whether the participant is covered under the law. Therefore, prices for the base year and all option years shall not exceed the annually established Federal Ceiling Price (FCP), plus the 0.5% Cost Recovery Fee (CRF). Attention is directed to the fact that although 38 U.S.C. § 8126 applies to all covered drugs, competitively negotiated and awarded prices for the base year and any option years exercised by the Government will govern unless the annually established FCP results in a price lower than competitively awarded contract prices. In this instance, the contract shall be modified to reflect the lower annually established FCP, plus the 0.5% CRF. Both parties (Offeror and VA) understand the VA National Contract Service will obtain FCPs from VA’s Pharmacy Benefits Management (PBM). The parties agree the FCP will be calculated pursuant to the requirements of 38 U.S.C. § 8126 and any related requirements contained in the contractor’s Master Agreement, Pharmaceutical Pricing Agreement, and relevant VA Dear Manufacturer Letters. Refer to the VA Federal Supply Schedule (FSS) website at https://www.fss.va.gov/ and Public Law 102-585 (Veterans Health Care Act of 1992) page on the VA FSS website at https://www.va.gov/opal/nac/fss/publicLaw.asp for further information and a list of published Dear Manufacturer Letters. Contractors submitting a proposal for a covered drug are required to complete the following paragraph: MASTER AGREEMENTS AND PHARMACEUTICAL PRICING AGREEMENTS In compliance with 38 U.S.C. § 8126, Offerors of covered drug products (including biologics) must state below whether they currently have a Master Agreement (MA) and a Pharmaceutical Pricing Agreement (PPA), that includes the offered drug products/NDCs, in place with the Department of Veterans Affairs (VA) and confirm that the proposed covered drug products are present on the Offeror’s FSS contract or interim agreement. _____ YES, Offeror has an MA and PPA (inclusive of the proposed drug products/NDCs) in place with VA FSS and proposed drugs are present on Offeror’s FSS contract/interim agreement. _____ NO, Offeror does not have an MA and PPA (inclusive of the proposed drug products/NDCs) in place with VA FSS and/or products are not present on Offeror’s FSS contract/interim agreement. Offers of covered drugs (including biologics that fall within 21 CFR § 600.3) will only be considered for award if the Offeror has an executed MA and PPA (which includes the proposed drug products/NDCs) on file with the VA Enterprise Procurement Office, FSS (in accordance with 38 U.S.C. § 8126(h)(4)(B)). Furthermore, in order to be considered for award under this solicitation, all proposed covered drug products/NDCs must be present on the offeror’s FSS contract or interim agreement with an established Permanent FCP associated with the offeror’s FSS contract or interim agreement by this solicitation’s due date and time for receipt of offers. Offers failing to meet these criteria will be rejected and receive no further consideration. 12. COST RECOVERY FEE AND SUBMISSION OF QUARTERLY SALES REPORTS 12.1 Quarterly Sales Reports. The Contractor shall report all contract sales under this contract and submit collected Cost Recovery Fees as follows: (A) The Contractor shall accurately report the dollar value, in U.S. dollars and rounded to the nearest whole dollar, of all sales made under this contract by calendar quarter (January 1–March 31, April 1–June 30, July 1–September 30, and October 1–December 31). Reported sales must include all sales made to all authorized contract users, whether shipped directly to the users or through Prime Vendor contractors. The report shall reflect sales by contract line item and shall segment sales by the Department of Veterans Affairs (VA) and Other Government Agencies (OGA). A Cost Recovery Fee equivalent to 0.5 % of the current contract price shall be collected from all contract users. The 0.5 % Cost Recovery Fee shall be imbedded in the awarded contract prices, and offers submitted in response to this solicitation shall include the Cost Recovery Fee in every line item price offered. The reported contract sales shall include the Cost Recovery Fee and each quarterly report shall show the total Cost Recovery Fee amount collected on the reported sales. The Contractor shall maintain a consistent accounting method of sales reporting, based on the Contractor’s established commercial accounting practice. (B) Contract sales reports are due to the Contracting Officer within 30 calendar days following the completion of each reporting quarter or completion of the contract, whichever occurs first. A report is required even when no billings or invoices are issued or no orders are received during the contract period. (C) The sales report signed by an authorized representative of the contractor shall be emailed to the Contracting Officer. (D) In addition to the submission of quarterly sales reports due to the Contracting Officer within 30 calendar days after the end of each reporting quarter, contractors shall provide copies of sales reports simultaneously with contractor’s Cost Recovery Fee payment submissions via email to: [direct contact value redacted]. 12.2 The 0.5% Cost Recovery Fee amount shall be paid electronically via Collections Information Repository (CIR)/Automated Clearing House (ACH). CIR/ACH credit instructions will be provided to the contractor upon contract award. When the contractor has multiple national contracts, the fee may be consolidated into one electronic payment. When the electronic payment is made, the contractor shall submit an email to [direct contact value redacted] to identify the contract number (or numbers, if the payment covered multiple contracts) included, dollar amount remitted for each contract number, and reporting quarter. The Cost Recovery Fee payment is due to the VA Fiscal Division at the same time the sales report is due to the Contracting Officer (i.e., within 30 calendar days following the completion of each reporting quarter or completion of the contract). Cost Recovery Fee payments shall not be combined with any Industrial Fund Fee payments. Contractors shall remit separately any Industrial Fund Fee payments in support of any of the Contractor’s Federal Supply Schedule contracts. 12.3 The Government reserves the right to inspect without further notice, such records of the Contractor as pertain to sales under any contract resulting from this solicitation. Willful failure or refusal to furnish the required reports, or falsification thereof, shall constitute sufficient cause for terminating the contract under FAR 52.212-4(m), Contract Terms and Conditions - Commercial Products and Commercial Services, Termination for Cause. 12.4 Failure to remit the full amount of the Cost Recovery Fee within 30 calendar days after the end of the applicable reporting period constitutes a contract debt to the United States Government under the terms of FAR Subpart 32.6. The Government may exercise all rights under the Debt Collection Improvement Act of 1996, including withholding or setting off payments and interest on the debt (see FAR 52.212-4(i)(5)). Should the Contractor fail to submit the required sales reports, falsify them, or fail to timely pay the Cost Recovery Fee, the Government shall have, in addition to the rights and remedies described in this section, all other rights and remedies permitted by Federal law and statutes. 13. MANUFACTURING FACILITIES/PLACE OF PERFORMANCE 13.1 The FDA is the Government agency responsible for providing and enforcing pharmaceutical cGMP standards for human drugs, pharmaceutical products, biologics, medical devices, chemical products, medical cylinder oxygen, reagents, diagnostics, test kits and sets included in this solicitation. Only offers from companies that have an acceptable cGMP status on record with the FDA for the facilities identified by the offeror in Section 13.7 below will be considered for award. Before a contract can be awarded, any successful offeror’s manufacturing, packaging, and any other applicable facilities shall have a current acceptable cGMP status with the FDA, or shall have had an acceptable report from the last FDA facility inspection on record for the product type offered. In the absence of a current cGMP evaluation for any of the identified facilities, an offeror is required to include with its proposal documentation on the acceptable outcome of an FDA facility inspection that occurred within two years prior to submission of the offer. 13.2 If at any time during the life of the contract, the contractor’s facility (or the source from which the contractor obtains any of the products offered on this contract), or the facility that packages the product offered in this contract is notified of violations or potential violations by the FDA, is issued a Form FDA 483, or is issued an FDA Warning Letter highlighting a failure to meet FDA cGMPs (21 CFR Part 210 and 211), the awarded contractor shall inform the Contracting Officer within 15 calendar days of the notice. At which time, the Contracting Officer will apply the procedures outlined in Section 13.3 below. Non-timely notification may result in a negative past performance rating and/or be grounds for contract termination in accordance with FAR 52.212-4(m), Contract Terms and Conditions-Commercial Products and Commercial Services, Termination for Cause. 13.3 The Contracting Officer will review the contractor’s (or its source’s) unacceptable cGMP status with appropriate VHA clinical staff and will either: 1) instruct the contractor to stop the shipment of products listed on this contract that were manufactured and/or packaged in a facility with unacceptable cGMP status, or 2) authorize the contractor to continue to supply such contract products for 90 calendar days from the date when unacceptable cGMP status was communicated to VA EPO, provided that the products have not been subjected to a consumer-level recall. An additional 90 calendar day extension may be authorized at the discretion of the Contracting Officer. Contractors are cautioned that products that were manufactured and /or packaged in a facility with unacceptable cGMP status and then shipped without written authorization from the Contracting Officer shall be returned to the contractor at the contractor’s risk and expense. The contractor shall have corrected all significant cGMP deficiencies or have an acceptable plan with the FDA for the correction of such deficiencies which led to unacceptable status by the end of the 90-calendar day authorization period and any extensions of such period granted by the Contracting Officer. Additionally, the contractor is responsible for keeping the Contracting Officer informed of all corrections made and shall provide the Contracting Officer with: 1) written documentation of the correction plan, 2) Notification from FDA of acceptance of plan, and 3) a copy of any reinspection requests and subsequent reinspection reports, upon availability. If FDA’s evaluation of contractor’s (or its source’s) compliance efforts and/or re-inspection of the non-compliant facility does not result in an acceptable rating by the FDA within 90 calendar days from the date when unacceptable cGMP status was communicated to VA EPO, or by the end of a Contracting Officer’s authorization period (whichever is the greater period of time), the contract may be terminated for cause in accordance with FAR 52.212-4(m). The contractor’s (or its source’s) failure to correct the cGMP deficiencies in a timely manner shall not constitute or give rise to any “excusable delays” pursuant to FAR 52.212-4(f). (Nothing in this section shall be read as limiting the recognized grounds upon which a Contracting Officer may terminate this contract or delete products pursuant to the applicable sections contained in the contract.) 13.4 The contractor shall use only the FDA-inspected manufacturing facilities provided in Section 13.7, below, for the duration of the contract, unless substitution of manufacturing facilities is approved by the Contracting Officer. In case of any manufacturing facility relocation or substitution of manufacturing facilities, the contractor shall immediately notify the Contracting Officer of the pending change, and the contractor shall request approval from the Contracting Officer to supply the contracted products from the new location. If the change is approved by the Contracting Officer, after an inquiry to the FDA for cGMP status of the new location, approval will be provided by means of a formal contract modification. 13.5 If the products are to be manufactured at more than one location, each manufacturing facility and each facility address shall be listed along with the products manufactured at the facility. Subcontractors (i.e., packagers, labelers, etc.) that participate in the production of the products offered on this solicitation shall also be listed along with their addresses. All facilities described in this section and listed below shall be substantially in compliance with applicable FDA cGMP standards prior to contract award. 13.6 Offeror shall identify below or by attachment (if additional space is needed), the products offered on this solicitation (products shall be identified by product name and by solicitation item number); whether the offeror manufactures the products; and/or whether the offeror is a distributor of the products offered. Refer to the solicitation’s Continuation of Standard Form 1499: Schedule of Supplies/Services for the definition of “Manufacturer” for purposes of the Letter of Commitment and current Good Manufacturing Practices (cGMP) acceptability verifications. 13.7 The offeror is required to indicate below the complete name and address(es) of the manufacturer. The offeror is also required to check the box below that is applicable to its offer. Please note that the information required below must be the name and address of the manufacturing facility, rather than the address of the foreign headquarters, distributor or agent. ( ) OFFEROR IS THE MANUFACTURER (AT THE FOLLOWING LOCATIONS) OF THE PRODUCTS OFFERED ON THIS SOLICITATION. ( ) OFFEROR IS A DISTRIBUTOR OF THE PRODUCTS OFFERED ON THIS SOLICITATION. The offeror must maintain the same manufacturer (NDA/ANDA/BLA) for the duration of the contract period, unless the Contracting Officer makes a determination that a change in the manufacturer is acceptable. This determination may take place before or after contract award. THE PRODUCTS WILL BE MANUFACTURED BY THE FOLLOWING COMPANY AT THE FOLLOWING LOCATIONS: (Name of Manufacturing Company) (Street Address) (Post Office Address Not Acceptable) (U.S.A. Point of Contact, e-Mail Address and U.S.A Telephone Number) (FDA Establishment Identification [FEI] number of Manufacturing Company) PHARMACEUTICALS – PARENTERALS Solicitation Item # and Product Name | Location and owner of facility where ingredients are manufactured per definition in Scope of Contract, Section 13.6 (Facility Owner Name, Address, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number PHARMACEUTICALS – PARENTERALS, STERILIZATION Solicitation Item # and Product Name | Sterilization and owner location (Facility Owner Name, Address, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number ACTIVE PHARMACEUTICAL INGREDIENT (Also known as drug substance or bulk substance) Solicitation Item # and Product Name | Location and owner where active pharmaceutical ingredient is created (Facility Owner Name, Address, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number TABLETS, CAPSULES, AND PILLS Solicitation Item # and Product Name | Location and owner of facility where ingredients are manufactured per definition in Scope of Contract, Section 13.6 (Facility Owner Name, Address, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number OTHER PHARMACEUTICAL PRODUCTS (Solutions, syrups, mixtures, powders, ointments, pastes, creams, etc.) Solicitation Item # and Product Name | Location and owner of facility where ingredients are manufactured per definition in Scope of Contract, Section 13.6 (Facility Owner Name, Address, City, County, State and Zip Code | Point of Contact, Including Phone # | FEI Number PACKAGING (If product is repackaged, include both packaging and repackaging locations) Solicitation Item # and Product Name | Location of facilities where Intermediate containers will be filled and labeled (Facility Name, Location, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number PACKING Solicitation Item # and Product Name | Location of facilities where products will be packed and prepared for shipment (Facility Name, Location, City, County, State and Zip Code) | Point of Contact, Including Phone # | FEI Number 14. INCORPORATION OF DOCUMENTS The following documents are hereby incorporated by reference and made a part of this solicitation. The United States Pharmacopeia-National Formulary (USP-NF) designation "USP" and "NF" shall be considered interchangeable when monographs for ingredients or preparations are transferred from one official compendium to the other. For ingredients or preparations which no longer appear in the latest revision of the USP or NF, the previous volume shall apply. Ingredients or preparations for which monographs appear for the first time in the Official Compendia shall comply with the applicable monographs unless the word "modified" appears as part of the item name. The requirements that an item or ingredient comply with test standards and requirements of the USP or the NF does not delete any other applicable portions of the compendia, such as, but not limited to, General Notices. Thus, for USP-NF items, alternative test methods are permitted. AMERICAN CHEMICAL SOCIETY (ACS), Reagent Chemicals, American Chemical Society Specifications. Information about ACS Reagent Chemicals can be found at https://pubs.acs.org/. U. S. DEPARTMENT OF HEALTH, EDUCATION AND WELFARE, FOOD AND DRUG ADMINISTRATION (FDA). Federal Food, Drug, and Cosmetic Act and Regulations promulgated thereunder. FDA Rules and Regulations can be found at https://www.fda.gov/regulatory-information/fda-rules-and-regulations and can be found under Title 21 of the Code of Federal Regulation at https://www.ecfr.gov/. U. S. PHARMACOPEIAL CONVENTION, INC. (USP-NF). Pharmacopoeia of the United States. Information about USP/NF can be found at https://www.uspnf.com/. (g) Invoice. The Government will handle invoices according to the Prompt Payment Act (31 U.S.C. 3903) and 5 CFR part 1315. The Contractor shall submit invoices to the address designated in the contract to receive invoices. An invoice must include the information required by 5 CFR part 1315.9(b). (h) Patent indemnity. The Contractor shall indemnify the Government and its officers, employees, and agents against liability, including costs, for actual or alleged direct or contributory infringement of, or inducement to infringe, any United States or foreign patent, trademark, or copyright, arising out of the performance of this contract, provided the Contractor is reasonably notified of such claims and proceedings. (i) Payment— (1) Items accepted. Payment shall be made for items accepted by the Government that have been delivered to the delivery destinations set forth in this contract. (2) Prompt payment. The Government will make payment in accordance with the Prompt Payment Act ( 31 U.S.C. 3903) and prompt payment regulations at 5 CFR part 1315. (3) Discount. In connection with any discount offered for early payment, time shall be computed from the date of the invoice. For the purpose of computing the discount earned, payment shall be considered to have been made on the date that appears on the payment check or the specified payment date if an electronic funds transfer payment is made. (4) Overpayments. If the Contractor becomes aware of a duplicate contract financing or invoice payment or that the Government has otherwise overpaid on a contract financing or invoice payment, the Contractor shall— (i) Remit the overpayment amount to the payment office cited in the contract along with a description of the overpayment including the— (A) Circumstances of the overpayment (e.g., duplicate payment, erroneous payment, liquidation errors, date(s) of overpayment); (B) Affected contract number and delivery order number, if applicable; (C) Affected line item or subline item, if applicable; (D) Contractor point of contact; and (ii) Provide a copy of the remittance and supporting documentation to the Contracting Officer. (5) Interest.(i) All amounts that become payable by the Contractor to the Government under this contract shall bear simple interest from the date due until paid unless paid within 30 days of becoming due. The interest rate shall be the interest rate established by the Secretary of the Treasury as provided in 41 U.S.C. 7109, which is applicable to the period in which the amount becomes due, as provided in (i)(6)(v) of this clause, and then at the rate applicable for each six-month period as fixed by the Secretary until the amount is paid. (ii) The Government may issue a demand for payment to the Contractor upon finding a debt is due under the contract. (iii) Final decisions. The Contracting Officer will issue a final decision as required by FAR part 33 if– (A) The Contracting Officer and the Contractor are unable to reach agreement on the existence or amount of a debt within 30 days; (B) The Contractor fails to liquidate a debt previously demanded by the Contracting Officer within the timeline specified in the demand for payment unless the amounts were not repaid because the Contractor has requested an installment payment agreement; or (C) The Contractor requests a deferment of collection on a debt previously demanded by the Contracting Officer (see FAR part 32). (iv) If a demand for payment was previously issued for the debt, the demand for payment included in the final decision shall identify the same due date as the original demand for payment. (v) Amounts shall be due at the earliest of the following dates: (A) The date fixed under this contract. (B) The date of the first written demand for payment, including any demand for payment resulting from a termination for cause. (vi) The interest charge shall be computed for the actual number of calendar days involved beginning on the due date and ending on- (A) The date on which the designated office receives payment from the Contractor; (B) The date of issuance of a Government check to the Contractor from which an amount otherwise payable has been withheld as a credit against the contract debt; or (C) The date on which an amount withheld and applied to the contract debt would otherwise have become payable to the Contractor. (vii) The interest charge made under this clause may be reduced under the procedures for interest credits prescribed in FAR part 32 in effect on the date of this contract. (j) Risk of loss. Unless the contract specifically provides otherwise, risk of loss or damage to the supplies provided under this contract shall remain with the Contractor until, and shall pass to the Government upon— (1) Delivery of the supplies to a carrier, if transportation is f.o.b. origin; or (2) Delivery of the supplies to the Government at the destination specified in the contract, if transportation is f.o.b. destination. C.2 ADDENDUM to FAR 52.212-4 CONTRACT TERMS AND CONDITIONS--COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES 1. Ordering. This solicitation provides for the award of a contract in support of VA’s standardization program. Products awarded on the resultant contract will be distributed through Government Prime Vendor contract(s). Order placement for supplies awarded will be made by Government Prime Vendor contractor(s) to the awarded contractor and, any supplies to be furnished under this contract shall be ordered by issuance of delivery orders by the individuals or facilities directly to Prime Vendor contractor(s). Government Prime Vendor contractor(s) will accept orders and payment for the contracted item(s) on behalf of the Contractor. Such orders may be issued from the first day of the ordering period of the contract through the expiration date of the final option period exercised. All delivery orders are subject to the terms and conditions of this contract. In the event of conflict between a delivery order and this contract, the contract shall control. 2. Delivery. Delivery order requirements such as product quantities, time and place of delivery, and method of delivery for product(s) awarded on resultant contract will be determined between the awarded Contractor and Government Prime Vendor contractors. 3. Assignment. Application of 52.212-4(c) Assignment is dependent upon the details of the business-to-business agreement between the contractor and Pharmaceutical Prime Vendor. 4. Chargeback Arrangements. Chargeback arrangements/agreements shall be coordinated between the Government Prime Vendor contractors and the successful Contractor. The Government will not become involved in this area nor will the Government assume any responsibility for any monies involved with such arrangements. 5. Inspection/Acceptance. Products will be ordered by the Government through Government Prime Vendor contracts. The Government’s inspection rights become effective upon receipt at the Government ordering facility. 6. Risk of Loss. Unless the contract specifically provides otherwise, risk of loss or damage to the supplies provided under this contract shall remain with the Contractor, and shall pass to the Government upon delivery by the Contractor to any Government-contracted Prime Vendor contractor. C.3 52.216-21 REQUIREMENTS (VA DEVIATION NOV 2025) (a) This is a requirements contract for the supplies or services specified, and effective for the period stated, in the Schedule. The quantities of supplies or services specified in the Schedule are estimates only and are not purchased by this contract. Except as this contract may otherwise provide, if the Government's requirements do not result in orders in the quantities described as "estimated" or "maximum" in the Schedule, that fact shall not constitute the basis for an equitable price adjustment. (b) Delivery or performance shall be made only as authorized by orders issued in accordance with the Ordering clause. Subject to any limitations in the Order Limitations clause or elsewhere in this contract, the Contractor shall furnish to the Government all supplies or services specified in the Schedule and called for by orders issued in accordance with the Ordering clause. The Government may issue orders requiring delivery to multiple destinations or performance at multiple locations. (c) Except as this contract otherwise provides, the Government shall order from the Contractor all the supplies or services specified in the Schedule that are required to be purchased by the Government activity or activities specified in the Schedule. (d) The Government is not required to purchase from the Contractor requirements in excess of any limit on total orders under this contract. (e) If the Government urgently requires delivery of any quantity of an item before the earliest date that delivery may be specified under this contract, and if the Contractor will not accept an order providing for the accelerated delivery, the Government may acquire the urgently required goods or services from another source. (f) Any order issued during the effective period of this contract and not completed within that period shall be completed by the Contractor within the time specified in the order. The contract shall govern the Contractor's and Government's rights and obligations with respect to that order to the same extent as if the order were completed during the contract's effective period; provided, that the Contractor shall not be required to make any deliveries under this contract after 15 calendar days from the expiration date of the contract. C.4 ADDENDUM to FAR 52.216-21 REQUIREMENTS As detailed in the Addendum to FAR 52.212-4, products awarded on the resulting contract from this solicitation will be distributed through Government Prime Vendor contract(s). As such, details specific to contract(s) resulting from this solicitation regarding 52.216-21, Requirements, have been specified below. 1. Delivery or performance shall be made only as authorized by orders issued through Prime Vendor contract(s). Subject to any limitations specified in this contract, the Contractor shall deliver to the Prime Vendor contractor(s) the supplies specified in the Schedule and called for by orders issued by the Prime Vendor(s). Prime Vendor contractor(s) may issue orders requiring delivery to multiple Prime Vendor contractor distribution centers. 2. The Government shall order from the Contractor through the Prime Vendor contractor(s) all the supplies specified in the Schedule that are required to be purchased by the Department of Veterans Affairs and other Government agencies as specified in the Schedule. 3. If the Government urgently requires delivery of any quantity of an item that the Prime Vendor contractors(s) do not have available for delivery as required by the Prime Vendor contract terms, the Government may acquire the urgently required item(s) from any other available source. 4. Any order(s) issued by the Prime Vendor contractor(s) during the ordering period of this contract and not completed within the ordering period shall be completed by the Contractor within the time specified in the Prime Vendor contractor issued order. This contract shall govern the rights and obligations between the Contractor(s) of this contract, the Prime Vendor contractor(s) and the Government with respect to the order(s) to the same extent as if the order(s) were completed during the contract period, provided that, the Contractor shall not be required to make any deliveries under this contract after 15 calendar days from the expiration date of the contract. SECTION E - SOLICITATION PROVISIONS E.1 52.212-1 INSTRUCTIONS TO OFFERORS--COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES (VA DEVIATION 2025) (a) Submission of offers. Submit signed and dated offers to the office specified in this solicitation at or before the exact time specified in this solicitation. As a minimum, offers shall include— (1) The solicitation number; (2) The name, address, telephone number of the Offeror; (3) The Offeror’s Unique Entity Identifier (UEI) and, if applicable, Electronic Funds Transfer (EFT) indicator; (4) Information necessary to evaluate the factors contained in the provision at 52.212-2 or as described in the solicitation; (5) Responses to provisions that require Offeror completion of information, representations, and certifications (other than those collected via the System for Award Management (SAM)); and (6) A statement specifying the extent of agreement with all terms, conditions, and provisions included in the solicitation and any solicitation amendments. (b) Period for acceptance of offers. (Tailored) The Offeror agrees to hold the prices in its offer firm for 120 calendar days from the date specified for receipt of offers, unless another time period is specified in an addendum to the solicitation. (c) Late submissions, modifications, revisions, and withdrawals of offers. (1) Offerors are responsible for submitting offers and any modifications or revisions to the Government office designated in the solicitation by the time specified in the solicitation. (2) Any offer, modification, or revision received after the time specified for receipt of offers is “late” and will not be considered unless it is received before award is made and the Contracting Officer determines that accepting the late offer would not unduly delay the acquisition. However, a late modification of an otherwise successful offer that makes its terms more favorable to the Government will be considered at any time it is received and may be accepted. (3) If an emergency or unanticipated event interrupts normal Government processes so that offers cannot be received at the Government office designated for receipt of offers by the exact time specified in the solicitation, and urgent Government requirements preclude amendment of the solicitation or other notice of an extension of the closing date, the time specified for receipt of offers will be deemed to be extended to the same time of day specified in the solicitation on the first work day on which normal Government processes resume. (4) Offerors may withdraw their offers by written notice to the Government received at any time before award. (d) Contract award (not applicable to Invitation for Bids). The Government intends to evaluate offers and award a contract without discussions with Offerors. Therefore, the Offeror’s initial offer should contain the Offeror’s best terms. However, the Government reserves the right to conduct discussions, if necessary. The Government may reject any or all offers if such action is in the public interest, accept other than the lowest offer, and waive informalities and minor irregularities in offers received. (e) Debriefings. If a postaward debriefing is given to requesting Offerors, the Government will disclose the following information, if applicable: (1) The agency’s evaluation of the significant weak or deficient factors in the debriefed Offeror’s offer. (2) The overall evaluated cost or price and technical rating of the successful Offeror and the debriefed Offeror and past performance information on the debriefed Offeror. (3) The overall ranking of all Offerors when any ranking was developed by the agency during source selection. (4) A summary of the rationale for award. (5) For acquisitions of commercial products, the make and model of the product to be delivered by the successful Offeror. (6) Reasonable responses to relevant questions posed by the debriefed Offeror as to whether the agency followed source-selection procedures set forth in the solicitation, applicable regulations, and other applicable authorities. E.2 ADDENDUM to FAR 52.212-1 INSTRUCTIONS TO OFFERORS --COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES Instructions for Proposal Submission 1) Proposals will be accepted in Microsoft Word or PDF form via e-mail to [direct contact value redacted] at [direct contact value redacted] and [direct contact value redacted] with a scanned (pdf) copy of the signed SF-1449.  Please note that faxed proposals are not acceptable and will be rejected. Please note, zip files and folders are rejected by VA EPO servers, and emails with large attachments may not be received. VA suggests that offerors submit their proposals well before the deadline and confirm receipt of all attachments with the Contracting Officer listed on the SF-1449. Should an offeror submit multiple offerors, each offer will be evaluated individually. 2) Offerors shall include its Unique Entity Identifier and Contractor and Government Entity (CAGE) code in block 17a of the SF-1449. 3) For each item offered, offerors shall provide a separate and distinct 11-digit National Drug Code (NDC) Number unique to the offeror as outlined in the Scope of Contract (Section 8). 4) Offerors shall meet the packaging requirements as outlined in Scope of Contract (Section 5). 5) Offerors shall submit a price for all line items offered, inclusive of the base year and four option years. Offered prices must include 0.5% Cost Recovery Fee as outlined in the Scope of Contract (Section 12). 6) Offerors shall complete the solicitation representations at FAR 52.209-7 and FAR 52.219-1, as provided in Section E of the solicitation. 7) Country of Origin and VA’s interpretation of substantial transformation of pharmaceuticals. Offerors shall complete as applicable the certification at FAR 52.225-6. An article is a product of a country or instrumentality only if (i) it is wholly the growth, product, or manufacture of that country or instrumentality, or (ii) in the case of an article which consists in whole or in part of materials from another country or instrumentality, it has been substantially transformed into a new and different article of commerce with a name, character, or use distinct from that of the article or articles from which it was so transformed. See 19 U.S.C. § 2518(4)(B). For purposes of determining compliance with the Trade Agreements Act (TAA) (19 U.S.C. § 2512), the Government will evaluate the country of origin of offered pharmaceutical products to determine if the proposed products are U.S.-made or designated country end products (designated country is defined in FAR Part 25). Products in which final manufacturing occurs in the United States will be considered U.S.-made end products, regardless of the location of the active pharmaceutical ingredient (API) creation. Nonetheless, offerors of U.S.-made product shall disclose the API creation information requested in the solicitation’s Scope of Contract. For products manufactured outside the United States, the Government will evaluate the manufacturing processes performed and the location of these processes to determine whether the product was substantially transformed in a designated country on a case-by-case basis. When final manufacturing of single-API pharmaceuticals occurs outside the United States, the Government generally considers the country of origin to be determined by the location of API creation. Activities such as simple blending or mixing of inactive ingredients with the API, or compressing the mixture into a tablet or similar finished dosage form, will generally not be considered to constitute substantial transformation. For pharmaceuticals with multiple APIs, the Government typically interprets the country of origin as the location where final manufacturing occurs, as multiple APIs are combined, thus undergoing substantial transformation and resulting in a new product. However, because pharmaceutical manufacturing processes may vary, the Government reserves the right to evaluate the specific manufacturing process on a case-by-case basis to determine whether a substantial transformation has occurred. Note that at no time is product repackaging considered relevant to a pharmaceutical’s country of origin. Offerors shall provide sufficient supporting documentation with their proposal to substantiate the certified country of origin and the location of manufacturing processes relevant to the Government’s evaluation. Such documentation may include, but is not limited to, descriptions of the manufacturing processes, identification of manufacturing locations, and supporting statements from the manufacturer. In making its determination, the Government may consider relevant guidance and rulings issued by U.S. Customs and Border Protection regarding substantial transformation; however, the Government will not rely solely on such rulings. The Contracting Officer reserves the right to request additional information as necessary and will make the final determination regarding country of origin. Please reach out to the Contracting Officer specified in this solicitation for any questions concerning applicable or relevant information. Failure to provide adequate supporting documentation by the due date and time for offers or other deadlines specified by the Contracting Officer may result in the offerors’ products being determined to be end products of non-designated countries. 8) Subcontracting Plan Requirements: Pursuant to the requirements of Public Law 95-507 (15 U.S.C. § 644), all other than small business concerns are required to have an approved subcontracting plan for contracts valued over $900,000 before the Government can award a contract (see FAR 52.219-9 and VAAR 852.219-70 for details). Offerors must submit a currently approved commercial plan or a new plan for review and approval. Attachment “D” includes all of the elements required to be addressed and is included to facilitate the submission of a subcontracting plan. 9) SAM is the Official U.S. Government system for registering to do business with the federal government, completing company representations and certifications, listing contract opportunities, and more. Contractors/Offerors should go to http://www.sam.gov to find their information. Training tools are available on the SAM website for familiarization with the SAM system. Prospective contractors shall maintain an uninterrupted, current, and accurate record in the SAM database at the time of proposal submission, during evaluation, and during contract performance. SAM updates are required as necessary, but at least annually. Please indicate below the offeror’s SAM Unique Entity Identifier, DUNS number, and Tax ID Number (TIN) for SAM verification purposes: SAM Unique Entity Identifier:  _________________________ DUNS:                                    _________________________ TIN:                                    _________________________ 10) CONTRACTOR POINTS OF CONTACT Offerors shall indicate the individuals responsible for contract administration and for the submission of sales reports/Cost Recovery Fees. Contract Administration Point of Contact Name and Title ________________________________________________ Address ________________________________________________ City, State, Zip Code ________________________________________________ Email Address ________________________________________________ Phone Number ________________________________________________ Sales Report Point of Contact Name and Title ________________________________________________ Email Address ________________________________________________ Phone Number ________________________________________________ 11) AUTHORIZED NEGOTIATORS The offeror represents that the following persons are authorized to negotiate on its behalf with the Government in connection with this request for proposals: (list names, titles, e-mail addresses, and telephone numbers of the authorized negotiators) ____________________________________________________________________________ ____________________________________________________________________________ ____________________________________________________________________________ ____________________________________________________________________________ 12) NOTICE TO DEALERS AND SUPPLIERS (a) If the offeror is not the manufacturer of the offered items, the offeror shall submit: A Letter of Commitment from the manufacturer to the offeror which will assure the offeror of a source of supply sufficient to satisfy the Government's requirements for the contract period. Refer to the solicitation’s Continuation of Standard Form 1499: Schedule of Supplies/Services for the definition of “Manufacturer” for purposes of the Letter of Commitment and current Good Manufacturing Practices (cGMP) acceptability verifications. If the offeror and its manufacturer are affiliates, the Letter of Commitment or evidence as required herein is required of the manufacturing facility, regardless of the relationship with the offeror. The offeror must maintain the same manufacturer and NDA/ANDA/BLA for the duration of the contract period, unless the Contracting Officer makes a determination that a change in the manufacturer is acceptable. This determination may take place before or after contract award. If not a manufacturer, to be eligible for award, offerors must submit a Letter of Commitment that meets all requirements stated in section (b) below. (b) To be considered acceptable, the Letter of Commitment: Shall be on the manufacturer’s letterhead. Shall be dated. Shall reference the solicitation number and the product committed to the manufacture. Shall state that the manufacturer assures the offeror of an uninterrupted source of supply sufficient to satisfy the Government’s requirements for the contract period, and that the manufacturer is currently manufacturing the product. Shall disclose the country of API creation and the country of origin for the proposed products. Refer to FAR 52.225-5, FAR 52.225-6, and the language in Section 13 of the solicitation’s Scope of Contract and Section 7 of the solicitation’s Addendum to FAR 52.212-1 Instructions to Offerors – Commercial Products and Commercial Services for relevant information and definitions. Shall be signed by an officer of the manufacturer’s company (include printed name, title and telephone number). E.3 52.209-7 INFORMATION REGARDING RESPONSIBILITY MATTERS (VA DEVIATION NOV 2025) (a) Definitions. As used in this provision— Administrative proceeding means a non-judicial process that is adjudicatory in nature in order to make a determination of fault or liability (e.g., Securities and Exchange Commission Administrative Proceedings, Civilian Board of Contract Appeals Proceedings, and Armed Services Board of Contract Appeals Proceedings). This includes administrative proceedings at the Federal and State level but only in connection with performance of a Federal contract or grant. It does not include agency actions such as contract audits, site visits, corrective plans, or inspection of deliverables. Federal contracts and grants with total value greater than $10,000,000 means— (1) The total value of all current, active contracts and grants, including all priced options; and (2) The total value of all current, active orders including all priced options under indefinite-delivery, indefinite-quantity, 8(a), or requirements contracts (including task and delivery and multiple-award Schedules). Principal means an officer, director, owner, partner, or a person having primary management or supervisory responsibilities within a business entity (e.g., general manager; plant manager; head of a division or business segment; and similar positions). (b) The offeror [_] has [_] does not have current active Federal contracts and grants with total value greater than $10,000,000. (c) If the offeror checked "has" in paragraph (b) of this provision, the offeror represents, by submission of this offer, that the information it has entered in the Federal Awardee Performance and Integrity Information System (FAPIIS) is current, accurate, and complete as of the date of submission of this offer with regard to the following information: (1) Whether the offeror, and/or any of its principals, has or has not, within the last five years, in connection with the award to or performance by the offeror of a Federal contract or grant, been the subject of a proceeding, at the Federal or State level that resulted in any of the following dispositions: (i) In a criminal proceeding, a conviction. (ii) In a civil proceeding, a finding of fault and liability that results in the payment of a monetary fine, penalty, reimbursement, restitution, or damages of $5,000 or more. (iii) In an administrative proceeding, a finding of fault and liability that results in– (A) The payment of a monetary fine or penalty of $5,000 or more; or (B) The payment of a reimbursement, restitution, or damages in excess of $100,000. (iv) In a criminal, civil, or administrative proceeding, a disposition of the matter by consent or compromise with an acknowledgment of fault by the Contractor if the proceeding could have led to any of the outcomes specified in paragraphs (c)(1)(i), (c)(1)(ii), or (c)(1)(iii) of this provision. (2) If the offeror has been involved in the last five years in any of the occurrences listed in (c)(1) of this provision, whether the offeror has provided the requested information with regard to each occurrence. (d) The offeror shall post the information in paragraphs (c)(1)(i) through (c)(1)(iv) of this provision in FAPIIS as required through maintaining an active registration in the System for Award Management, which can be accessed via https://www.sam.gov (see 52.204-7). E.4 52.219-1 SMALL BUSINESS PROGRAM REPRESENTATIONS (VA DEVIATION NOV 2025) (a) Definitions. As used in this provision- Economically disadvantaged women-owned small business (EDWOSB) concern means a small business concern that is at least 51 percent directly and unconditionally owned by, and the management and daily business operations of which are controlled by, one or more women who are citizens of the United States and who are economically disadvantaged in accordance with 13 CFR part 127, and the concern is certified by SBA or an approved third-party certifier in accordance with 13 CFR 127.300. It automatically qualifies as a women-owned small business concern eligible under the WOSB Program. HUBZone small business concern means a small business concern that meets the requirements described in 13 CFR 126.200, is certified by the Small Business Administration (SBA) and designated by SBA as a HUBZone small business concern in the Small Business Search (SBS) ( 13 CFR 126.103). Service-disabled veteran-owned small business (SDVOSB) concern eligible under the SDVOSB Program means an SDVOSB concern that is designated in the System for Award Management (SAM) as certified by the Small Business Administration (SBA) in accordance with 13 CFR 128.300. Small business concern— (1) Means a concern, including its affiliates, that is independently owned and operated, not dominant in its field of operation, and qualified as a small business under the criteria in 13 CFR part 121 and the size standard in paragraph (b) of this provision. (2) Affiliates, as used in this definition, means business concerns, one of whom directly or indirectly controls or has the power to control the others, or a third party or parties control or have the power to control the others. In determining whether affiliation exists, consideration is given to all appropriate factors including common ownership, common management, and contractual relationships. SBA determines affiliation based on the factors set forth at 13 CFR 121.103. Small disadvantaged business concern means a small business concern that- (1) Is at least 51 percent unconditionally and directly owned (as defined at 13 CFR 124.105) by one or more socially disadvantaged (as defined at 13 CFR 124.103) and economically disadvantaged (as defined at 13 CFR 124.104) individuals who are citizens of the United States, and (2) The management and daily business operations of which are controlled (as defined at 13 CFR 124.106) by individuals who meet the criteria in paragraph (1) of this definition. Women-owned small business (WOSB) concern eligible under the WOSB Program (in accordance with 13 CFR part 127) means a small business concern that is at least 51 percent directly and unconditionally owned by, and the management and daily business operations of which are controlled by, one or more women who are citizens of the United States, and the concern is certified by SBA or an approved third-party certifier in accordance with 13 CFR 127.300. (b) (1) The North American Industry Classification System (NAICS) code for this acquisition is 325412. (2) The small business size standard is 1,300 employees. (3) The small business size standard for a concern that submits an offer, other than on a construction or service acquisition, but proposes to furnish an end item that it did not itself manufacture, process, or produce (i.e., nonmanufacturer), is 500 employees, or 150 employees for information technology value-added resellers under NAICS code 541519, if the acquisition— (i) Is set aside for small business and has a value above the simplified acquisition threshold; (ii) Uses the HUBZone price evaluation preference regardless of dollar value, unless the offeror waives the price evaluation preference; or (iii) Is an 8(a), HUBZone, service-disabled veteran-owned, economically disadvantaged women-owned, or women-owned small business set-aside or sole-source award regardless of dollar value. (c) Representations. (1) The offeror represents as part of its offer that— (i) it □ is, □ is not a small business concern; or (ii) It □ is, □ is not a small business joint venture that complies with the requirements of 13 CFR 121.103(h) and 13 CFR 125.8(a) and (b). [ The offeror shall enter the name and unique entity identifier of each party to the joint venture: __.] (2) [Complete only if the offeror represented itself as a small business concern in paragraph (c)(1) of this provision.] The offeror represents that it □ is, □ is not a women-owned small disadvantage business concern. (3) Women-owned small business (WOSB) joint venture eligible under the WOSB Program. The offeror represents as part of its offer that it □ is, □ is not a joint venture that complies with the requirements of 13 CFR 127.506(a) through (c). [ The offeror shall enter the name and unique entity identifier of each party to the joint venture: __.] (4) Economically disadvantaged women-owned small business (EDWOSB) joint venture. The offeror represents as part of its offer that it □ is, □ is not a joint venture that complies with the requirements of 13 CFR 127.506(a) through (c). [ The offeror shall enter the name and unique entity identifier of each party to the joint venture: __.] (5) SDVOSB joint venture eligible under the SDVOSB Program. [Complete only if the offeror is certified as a SDVOSB concern]. The offeror represents as part of its offer that it □ is, □ is not a SDVOSB joint venture eligible under the SDVOSB Program that complies with the requirements of 13 CFR 128.402. [ The offeror shall enter the name and unique entity identifier of each party to the joint venture:__.] (6) HUBZone joint venture eligible under the HUBZone Program. [Complete only if the offeror is a HUBZone small business concern.] The offeror represents, as part of its offer, that it □ is, □ is not a HUBZone joint venture that complies with the requirements of 13 CFR 126.616(a) through (c). [ The offeror shall enter the name and unique entity identifier of each party to the joint venture: __.] Each HUBZone small business concern participating in the HUBZone joint venture must be certified as a HUBZone concern. (d) Notice. Under 15 U.S.C. 645(d), any person who misrepresents a firm’s status as a business concern that is small, HUBZone small, small disadvantaged, service-disabled veteran-owned small, economically disadvantaged women-owned small, or women-owned small eligible under the WOSB Program in order to obtain a contract to be awarded under the preference programs established pursuant to section 8, 9, 15, 31, and 36 of the Small Business Act or any other provision of Federal law that specifically references section 8(d) for a definition of program eligibility, will be— (1) Punished by imposition of fine, imprisonment, or both; (2) Subject to administrative remedies, including suspension and debarment; and (3) Ineligible for participation in programs conducted under the authority of the Act. E.5 52.225-6 TRADE AGREEMENTS CERTIFICATE (FEB 2021) (a) The offeror certifies that each end product, except those listed in paragraph (b) of this provision, is a U.S.-made or designated country end product, as defined in the clause of this solicitation entitled "Trade Agreements." (b) The offeror shall list as other end products those end products that are not U.S.-made or designated country end products. Other End Products: Line Item No. | Country of Origin _______________ | __________________ _______________ | __________________ ______________ | __________________ [List as necessary] (c) The Government will evaluate offers in accordance with the policies and procedures of part 25 of the Federal Acquisition Regulation. For line items covered by the WTO GPA, the Government will evaluate offers of U.S.-made or designated country end products without regard to the restrictions of the Buy American statute. The Government will consider for award only offers of U.S.-made or designated country end products unless the Contracting Officer determines that there are no offers for such products or that the offers for such products are insufficient to fulfill the requirements of the solicitation. E.6 52.216-1 TYPE OF CONTRACT (VA DEVIATION NOV 2025) The Government contemplates award of a Firm Fixed Price, Indefinite-Delivery Requirements contract resulting from this solicitation. E.7 52.233-2 SERVICE OF PROTEST (VA DEVIATION NOV 2025) (a) Protests, (as defined in FAR 33.102), that are filed directly with an agency, and copies of any protests that are filed with the Government Accountability Office (GAO), must be served on the Contracting Officer identified in the solicitation by obtaining written and dated acknowledgment of receipt from them. Email Addresses: [direct contact value redacted] [direct contact value redacted] [direct contact value redacted] [direct contact value redacted] (b) The copy of any protest must be received in the office designated above within one day of filing a protest with the GAO. E.8 52.212-2 EVALUATION—COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES (VA DEVIATION NOV 2025) A contract will be awarded to the responsible offeror that submits an offer meeting the solicitation requirements, and is the lowest price technically acceptable offer. An offer will be considered to be technically acceptable if it meets all the following criteria: The offered items must fully meet the product description, to include, the drug name, strength(s), and package size(s), as stated in the Schedule of Supplies. The National Drug Code (NDC) number of each offered product must be unique to the offeror. All offered pharmaceuticals must be Food and Drug Administration (FDA) approved. The FDA approval(s) must be verifiable by the Contracting Officer. All places of performance identified in the Scope of Contract, Section 13.7, must be FDA cGMP Acceptable for the product type offered. The FDA cGMP Acceptable status(es) must be verifiable by the Contracting Officer. The manufacturing facility must have clearance by the FDA to manufacture under the specific NDA/ANDA/BLA cited/used in the offer. The FDA clearance(s) must be verifiable by the Contracting Officer. One award will be made in the aggregate for line items 1, 2, and 3 including the base year and all four option years. In order to be considered for award, the offeror shall submit a price for line items 1, 2, and 3 for the base year and all four option years. Proposals that fail to include a price for the base year and each of the four option years for line items 1, 2, and 3 may be rejected and receive no further consideration. Offered prices shall include the 0.5% Cost Recovery Fee (see Scope of Contract, Section 12). The price evaluation will be computed by multiplying the estimated quantity of the line item by the unit prices offered for the base year and option years and adding the results of all line items. Unit prices offered shall not exceed two decimal places. The Government intends to evaluate offers and award a contract without discussions with offerors. However, the Government reserves the right to conduct discussions if determined by the Contracting Officer to be necessary. The Government will evaluate offers in accordance with the policies and procedures of the FAR Part 12, Part 15, and Part 25. An award will be made on the basis of the lowest evaluated price of proposals meeting or exceeding the acceptability standards for non-cost factors. Past Performance will be evaluated to determine contractor responsibility in accordance with FAR Part 9. Options. The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the base requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s). A written notice of award or acceptance of an offer emailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer’s specified expiration time, the Government may accept an offer, whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. E.9 52.252-1 SOLICITATION PROVISIONS INCORPORATED BY REFERENCE (FEB 1998) This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at this/these address(es): https://www.acquisition.gov/content/far-index https://www.va.gov/oal/library/vaar/ FAR/VAAR Provision | Title | Date 52.203-11 | CERTIFICATION AND DISCLOSURE REGARDING PAYMENTS TO INFLUENCE CERTAIN FEDERAL TRANSACTIONS | SEPT 2024 52.203-18 | PROHIBITION ON CONTRACTING WITH ENTITIES THAT REQUIRE CERTAIN INTERNAL CONFIDENTIALITY AGREEMENTS OR STATEMENTS-REPRESENTATION | JAN 2017 52.204-7 | SYSTEM FOR AWARD MANAGEMENT | VA DEVIATION NOV 2025 52.214-34 | SUBMISSION OF OFFERS IN THE ENGLISH LANGUAGE | APR 1991 52.214-35 | SUBMISSION OF OFFERS IN U.S. CURRENCY | APR 1991 52.219-4 | NOTICE OF PRICE EVALUATION PREFERENCE FOR HUBZONE SMALL BUSINESS CONCERNS | VA DEVIATION NOV 2025 52.240-90 | SECURITY PROHIBITIONS AND EXCLUSIONS REPRESENTATIONS AND CERTIFICATIONS | VA DEVIATION NOV 2025 852.209-70 | ORGANIZATIONAL CONFLICTS OF INTEREST | OCT 2020 852.215-72 | NOTICE OF INTENT TO RE-SOLICIT | OCT 2019 852.233-70 | PROTEST CONTENT/ALTERNATIVE DISPUTE RESOLUTION | SEP 2018 852.233-71 | ALTERNATE PROTEST PROCEDURE | SEP 2018 E.10 52.252-5 AUTHORIZED DEVIATIONS IN PROVISIONS (NOV 2020) (a) The use in this solicitation of any Federal Acquisition Regulation (48 CFR chapter 1) provision with an authorized deviation is indicated by the addition of “(DEVIATION)” after the date of the provision. (b) The use in this solicitation of any Department of Veterans Affairs Acquisition Regulation System (48 CFR chapter 8) provision with an authorized deviation is indicated by the addition of “(DEVIATION)” after the name of the regulation.

October 12, 2026 · Version 1

Published

6505--Prednisolone 1% Ophthalmic Solution